Northwestern University Feinberg School of Medicine
Skip to main content

Search Trials

Trials
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
This randomized phase II trial is studying radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with recurrent end…
This randomized phase II trial is studying radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with recurrent endometrial cancer. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation therapy together with cisplatin is more effective than radiation therapy alone in treating patients with endometrial cancer.
Shahabi, ShohrehShahabi, Shohreh
NCT00492778 STU00002996
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibo…
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether erlotinib hydrochloride given together with panitumumab is more effective with or without irinotecan in treating patients with metastatic colorectal cancer. PURPOSE: This randomized phase II trial is studying giving erlotinib hydrochloride together with panitumumab to see how well it works with or without irinotecan hydrochloride as second-line therapy in treating patients with metastatic colorectal cancer.
Benson III, Al BBenson III, Al B
NCT00940316 STU00004101
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
The main objective of this study is to learn which sapacitabine treatment is more likely to keep the cancer in check for at least one year in AML patients who are at least 70 years of a…
The main objective of this study is to learn which sapacitabine treatment is more likely to keep the cancer in check for at least one year in AML patients who are at least 70 years of age or older and in MDS patients who are at least 60 years of age.
Altman, Jessica KAltman, Jessica K
NCT00590187 STU00004419
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer …
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma. Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (FDG-PET)/computed tomography (CT), may help diagnose if recurrent disease is likely. PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.
Winter, Jane NormaWinter, Jane Norma
NCT00118209 STU00004575
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be …
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with liver cancer that cannot be removed by surgery.
Salem, RiadSalem, Riad
NCT00530010 STU00011036
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells m…
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with metastatic liver cancer that cannot be removed by surgery.
Salem, RiadSalem, Riad
NCT00532740 STU00011037
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Len…
This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cell. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
Frankfurt, OlgaFrankfurt, Olga
NCT00843882 STU00011947
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
This randomized phase III trial studies carboplatin and paclitaxel to see how well they work with or without cisplatin a…
This randomized phase III trial studies carboplatin and paclitaxel to see how well they work with or without cisplatin and radiation therapy in treating patients with stage I, stage II, stage III, or stage IVA endometrial cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether carboplatin and paclitaxel are more effective with or without cisplatin and radiation therapy in treating patients with endometrial cancer.
Shahabi, ShohrehShahabi, Shohreh
NCT00942357 STU00018576
More Info

For more information on this study please contact us:

1-855-NU-STUDY
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, …
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.
Winter, Jane NormaWinter, Jane Norma
NCT00822120 STU00020976
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different wa…
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer. PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy.
Some of the eligibility criteria include:

- Participants must be 18 years old or older.
- Participants must have undergone radical hysterectomy prior to entering the study.
- Participants cannot be allergic to carboplatin, paclitaxel and/ or cisplatin.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Donnelly, EricDonnelly, Eric
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00980954 STU00021457
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
This randomized phase III trial is studying radiation therapy to see how well it works compared with or without trastuzumab in treating women with ductal ca…
This randomized phase III trial is studying radiation therapy to see how well it works compared with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
Donnelly, EricDonnelly, Eric
NCT00769379 STU00021706
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor ce…
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT00978458 STU00026337
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Make Better Choices
The average adult has a poor quality diet and sedentary lifestyle, but the best way to produce sustained healthy change remains unknown. The MBC2 intervention uses handheld technology to help individuals monitor and transmit information about their eati…
The average adult has a poor quality diet and sedentary lifestyle, but the best way to produce sustained healthy change remains unknown. The MBC2 intervention uses handheld technology to help individuals monitor and transmit information about their eating and activity remotely to a behavior coach. The proposed trial tests whether MBC2 intervention improves diet and activity more than a stress management control condition, and whether changing multiple health behaviors is best achieved by changing them all at the same time, or one after another.
Spring, BonnieSpring, Bonnie
NCT01249989 STU00028323
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal ti…
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This randomized phase II/III trial is studying how well image-guided radiosurgery or stereotactic body radiation therapy works and compares it to external-beam radiation therapy in treating patients with localized spine metastasis. (phase II completed as of 8-30-11)
Kalapurakal, John AKalapurakal, John A
NCT00922974 STU00027912
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and…
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.
Shulman, Lee PShulman, Lee P
NCT00005095 STU00005421
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
This randomized phase III trial is studying giving carboplatin, paclitaxel and gemcit…
This randomized phase III trial is studying giving carboplatin, paclitaxel and gemcitabine together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.
Shahabi, ShohrehShahabi, Shohreh
NCT00565851 STU00005425
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
This randomized phase III trial is studying chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treat…
This randomized phase III trial is studying chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.
Benson III, Al BBenson III, Al B
NCT01004978 STU00022384
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
This randomized phase I trial is studying inositol to see how well it works in preventing colorectal cancer in patients with colitis-associated dysplasia. Chemoprevention is the use of c…
This randomized phase I trial is studying inositol to see how well it works in preventing colorectal cancer in patients with colitis-associated dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent colorectal cancer.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT01111292 STU00024719
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
This phase II trial studies how well bendamustine hydrochloride works in treating patients with recurrent or progressive anaplastic glioma or glioblastoma. Drugs used in chemotherapy, …
This phase II trial studies how well bendamustine hydrochloride works in treating patients with recurrent or progressive anaplastic glioma or glioblastoma. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Kumthekar, PriyaKumthekar, Priya
NCT00823797 STU00033288
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, eith…
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.
Kumthekar, PriyaKumthekar, Priya
NCT00626990 STU00036280
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood fl…
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth or tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sunitinib malate and gemcitabine hydrochloride together is more effective than sunitinib malate alone in treating patients with kidney cancer. PURPOSE: This randomized phase II clinical trial is studying giving sunitinib malate together with or without gemcitabine hydrochloride to see how well they work in treating patients with advanced kidney cancer that cannot be removed by surgery.
Sosman, JeffreySosman, Jeffrey
NCT01164228 STU00036017
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer
This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works c…
This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine, ovarian, fallopian tube, or peritorium cavity cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether paclitaxel is more effective when given together with carboplatin or ifosfamide in treating patients with uterine, ovarian, fallopian tube, or peritorium cavity cancer.
Shahabi, ShohrehShahabi, Shohreh
NCT00954174 STU00037705
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Pemetrexed disodium may stop the growth of tumor cells by blocking some enzymes needed for cell growth. It is not yet known whether giving bevacizumab or pemetrexed disodium alone or in combination is more effective in treating non-squamous non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer.
Mohindra, NishaMohindra, Nisha
NCT01107626 STU00038892
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
The drug being studied is Trastuzumab, a medicine that is used to slow or stop the growth of cancerous tumors that are HER-2 positive. Patients are being asked to participate in this study because the…
The drug being studied is Trastuzumab, a medicine that is used to slow or stop the growth of cancerous tumors that are HER-2 positive. Patients are being asked to participate in this study because they have been diagnosed with having tumor cells in their spinal fluid. This study will investigate the safety and effects of this drug when given directly into the spinal fluid. Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01325207 STU00040150
More Info

For more information on this study please contact us:

1-855-NU-STUDY
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Vaccines may help the body build an effective immune response to kill …
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with bevacizumab after chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine together with bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery.
Mohindra, NishaMohindra, Nisha
NCT00828009 STU00040569
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to st…
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer. PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.
Benson III, Al BBenson III, Al B
NCT01150045 STU00041400
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work i…
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether giving bendamustine hydrochloride and rituximab together alone is more effective than giving bendamustine hydrochloride and rituximab together with bortezomib or lenalidomide in treating follicular lymphoma. PURPOSE: This randomized phase II trial is studying giving bendamustine hydrochloride and rituximab together with or without bortezomib followed by rituximab with or without lenalidomide to see how well they work in treating patients with high-risk stage II, stage III, or stage IV follicular lymphoma.
Winter, Jane NormaWinter, Jane Norma
NCT01216683 STU00042588
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (C…
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Giving alemtuzumab together with ofatumumab may kill more cancer cells
Ma, ShuoMa, Shuo
NCT01361711 STU00044115
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine…
RATIONALE: Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia.
Altman, Jessica KAltman, Jessica K
NCT01041703 STU00044579
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
RATIONALE: Early surgery may have fewer side effects and improve recovery. Palliative surgery or radiation therapy may help patients with advanced breast cancer live more comfortably.…
RATIONALE: Early surgery may have fewer side effects and improve recovery. Palliative surgery or radiation therapy may help patients with advanced breast cancer live more comfortably. It is not yet known whether early surgery is more effective than palliative therapy for advanced breast cancer. PURPOSE: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT01242800 STU00046528
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previous…
This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine together may kill more cancer cells.
Gordon, Leo I IGordon, Leo I I
NCT01476410 STU00046908
More Info

For more information on this study please contact us:

1-855-NU-STUDY
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial car…
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Hussain, MahaHussain, Maha
NCT01215136 STU00047727
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Peripheral Neuropathy Research Registry (PNRR)
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in t…
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in the future. The registry aims to help researchers’ access large amounts of information about people with PN. By using this registry, researchers will facilitate both basic and clinical research studies that will bring improved understandings of the etiology (origination) and pathogenesis (development) of PN. They will specifically ask why some patients with peripheral neuropathy develop neuropathic pain and others do not, and what the characteristics of patients with painful peripheral neuropathy are in terms of their symptoms, examination findings, and blood tests. Ultimately this research may result in improved diagnosis, more effective treatments, and possibly prevention.
Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral Neuropathy
Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00048864
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
The investigators would like to see if women at increased risk for breast cancer are likely to tolerate SDG daily for 12 months without significant side effects or changes in their m…
The investigators would like to see if women at increased risk for breast cancer are likely to tolerate SDG daily for 12 months without significant side effects or changes in their menstrual cycles. The investigators would also like to determine if Brevail® can reduce breast cancer pre-menopausal women.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT01276704 STU00049144
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as …
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial studies how well an accelerated course of higher per daily radiation therapy with concomitant boost works compared to standard per daily radiation therapy with a sequential boost in treating patients with early-stage breast cancer that was removed by surgery.
Hayes, John PHayes, John P
NCT01349322 STU00051796
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how …
This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with advanced pancreatic neuroendocrine tumors (PNET) that cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be an effective treatment for patients with PNET.
Kircher, SheetalKircher, Sheetal
NCT01465659 STU00053541
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anap…
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma. Specialized radiation therapy, such as hypofractionated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving hypofractionated radiation therapy together with temozolomide and bevacizumab may kill more tumor cells.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01478321 STU00053636
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels (800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with…
The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels (800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with relapsed or refractory acute myeloid leukemia (AML). Additional dose levels beyond 1200 mg/day may be considered based on safety and efficacy observations.
Frankfurt, OlgaFrankfurt, Olga
NCT01349049 STU00053687
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-r…
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.
Chandra, SunandanaChandra, Sunandana
NCT01274338 STU00053937
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This phase III clinical trial is studying how well giving tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemothe…
This phase III clinical trial is studying how well giving tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy works in treating patients with invasive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast cancer.
Gradishar, William JGradishar, William J
NCT01272037 STU00054693
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of …
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective with cisplatin or cetuximab in treating oropharyngeal cancer. PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to see how well it works in treating patients with oropharyngeal cancer.
Mittal, Bharat BMittal, Bharat B
NCT01302834 STU00055939
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating …
This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to kill tumor cells or stop them from growing. Giving monoclonal antibody therapy together with chemotherapy may kill more tumor cells.
Mulcahy, Mary FrancesMulcahy, Mary Frances
NCT01473940 STU00045323
More Info

For more information on this study please contact us:

1-888-NU-STUDY
TK008: Efficacy Study on the Strategy of Herpes Simplex Virus Thymidine Kinase (HSV-Tk) Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
The main objective of this randomized trial is To compare disease-free survival (DFS) in high risk leukemia patients who under…
The main objective of this randomized trial is To compare disease-free survival (DFS) in high risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of HSV-Tk donor lymphocytes or standard haploidentical HCT
Mehta, JayeshMehta, Jayesh
NCT00914628 STU00058127
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients rece…
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
Kulik, Laura MKulik, Laura M
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01556490 STU00059691
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chem…
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
Mulcahy, Mary FrancesMulcahy, Mary Frances
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01483027 STU00059821
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzyme…
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Agulnik, MarkAgulnik, Mark
NCT01462630 STU00061834
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways…
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vincristine sulfate, procarbazine hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill cancer cells. It is not yet know whether rituximab and combination chemotherapy are more effective when given with or without radiation therapy in treating patients with primary central nervous system lymphoma. PURPOSE: This randomized phase II trial studies how well giving rituximab and combination chemotherapy with or without radiation therapy works in treating patients with primary central nervous system lymphoma.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01399372 STU00062372
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treati…
This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with locally advanced cervical cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. External radiation therapy uses high-energy x rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether giving cisplatin and external and internal radiation therapy together with carboplatin and paclitaxel kills more tumor cells.
Donnelly, EricDonnelly, Eric
NCT01414608 STU00062184
More Info

For more information on this study please contact us:

1-888-NU-STUDY
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. PURPOSE: This randomized phas…
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. PURPOSE: This randomized phase II trial is studying PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy.
Benson III, Al BBenson III, Al B
NCT01333033 STU00063249
More Info

For more information on this study please contact us:

1-855-NU-STUDY
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by …
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Comparing results of diagnostic procedures, such as PET scan and CT scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating patients with limited-stage diffuse large B-cell lymphoma.
Kaplan, JasonKaplan, Jason
NCT01359592 STU00064010
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Repetitive Transcranial Magnetic Stimulation in Breast Cancer Patients With Depression and Anxiety
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression…
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression. You are being asked to take part in this study because you are a cancer patient in remission who is depressed currently. In the future, we hope to be able to use rTMS on depressed cancer patients who are actively receiving cancer treatment. However, since this is a preliminary study, we will only include patients in remission. Finally, anxiety often accompanies depression. So, we are also interested in understanding your current level of anxiety and how rTMS affects any anxiety that you might have. Your participation in this study will last for approximately seven weeks and will involve 31 visits.
Dokucu, Mehmet EDokucu, Mehmet E
NCT01701284 STU00063218
More Info

For more information on this study please contact us:

Fairchild, Melody Dawn 312 503 7071
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-1…
This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The primary objectives of this study are to assess the safety profile, to determine the maximum tolerated dose and establish the Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab. The dose escalation portion of the study will include approximately 30 subjects. Once the recommended phase two dose and schedule have been determined, up to 20 additional subjects will be enrolled in an expanded safety portion of the study.
Ma, ShuoMa, Shuo
NCT01682616 STU00065351
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Through a patient participation aid (PPA) the investigators hope to improve the psychosocial well-being of women diagnosed with metastatic breast cancer by empowering them to be active participants…
Through a patient participation aid (PPA) the investigators hope to improve the psychosocial well-being of women diagnosed with metastatic breast cancer by empowering them to be active participants in clinical encounters.
Wolf, MichaelWolf, Michael
NCT01811264 STU00064228
More Info

For more information on this study please contact us:

1-888-NU-STUDY
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
This is a Randomized, Open-Label, Phase 3 trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Be…
This is a Randomized, Open-Label, Phase 3 trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Pro, BarbaraPro, Barbara
NCT01578499 STU00065910
More Info

For more information on this study please contact us:

1-855-NU-STUDY
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
The purpose of this study is to evaluate overall survival in patients treated with HepaSphere/QuadraSphere compared to conventional transarterial chemoembolization with …
The purpose of this study is to evaluate overall survival in patients treated with HepaSphere/QuadraSphere compared to conventional transarterial chemoembolization with particle PVA.
Lewandowski, Robert JLewandowski, Robert J
NCT01387932 STU00064130
More Info

For more information on this study please contact us:

1-855-NU-STUDY
BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. The trial will examine whether monotherapy with BI 836858 is safe and t…
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. The trial will examine whether monotherapy with BI 836858 is safe and tolerable at escalating dose levels.
Altman, Jessica KAltman, Jessica K
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01690624 STU00065889
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
This randomized phase III trial studies how well methotrexate works compared to dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. Drugs used in …
This randomized phase III trial studies how well methotrexate works compared to dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. Drugs used in chemotherapy, such as methotrexate and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether methotrexate is more effective than dactinomycin in treating gestational trophoblastic disease.
Shahabi, ShohrehShahabi, Shohreh
NCT01535053 STU00066779
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Extended Varenicline Treatment for Smoking Among Cancer Patients
The purpose of this study is to compare two different smoking cessation treatments for people who have been diagnosed or been treated for cancer in the past 5 years. Participants will receive either standard varenicline (Chantix) treatm…
The purpose of this study is to compare two different smoking cessation treatments for people who have been diagnosed or been treated for cancer in the past 5 years. Participants will receive either standard varenicline (Chantix) treatment for 12 weeks or extended varenicline (Chantix) treatment for 24 weeks, in combination with brief behavior therapy.
1. 18 years of age or older who self-report smoking at least 5 cigarettes (menthol and non-menthol) per day, on average, for the last 6 months.
2. Current cancer diagnosis (all sites) or diagnosis within the past 5 years.
3. Able to use varenicline safely, based on a medical evaluation including medical history and physical examination, and psychiatric evaluation.
Hitsman, Brian LHitsman, Brian L
NCT01756885 STU00064871
More Info

For more information on this study please contact us:

Maloney, Michael 1 877 236 7487
Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase III trial studies diet and physical activity changes to see how well they wor…
This randomized phase III trial studies diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival in patients with previously treated stage II, III, or IV ovarian, fallopian tube, or primary peritoneal cancer. A healthy lifestyle and counseling after treatment may improve progression-free survival in patients with previously treated cancer.
Shahabi, ShohrehShahabi, Shohreh
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00719303 STU00066809
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.…
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high energy x-rays to kill cancer cells. Giving chemotherapy together with radiation therapy may kill more cancer cells. Diagnostic procedures, such as PET scan, done before, during, and after chemotherapy may help doctors plan the best treatment. PURPOSE: This phase II clinical trial is studying how well response-based therapy assessed by PET scan works in treating patients with bulky stage I and stage II Hodgkin lymphoma.
Pro, BarbaraPro, Barbara
NCT01118026 STU00066977
More Info

For more information on this study please contact us:

1-855-NU-STUDY
The Genetics of Prostate Cancer in Active Surveillance
Our study uses saliva samples to detect whether or not active surveillance is the best option for the subject, based on their their genetic makeup and susceptibility to aggressive prostate cancer.
1. Patients diagnosed with prostate cancer
2. Patients with Gleason ≤ 3+3 prostate cancer
3. Patients with fewer than 3 cores involved with cancer. If a patient has 3 or more cores involved with cancer but still meets all pathologic criteria and after discussing risks and benefits does not want definitive treatment, he may still be eligible for active surveillance.
4. Patients with no more than 50% of any 1 core involved with prostate cancer. If a patient has more than 50% of any 1 core involved with prostate cancer but still meets all pathologic criteria and after discussing risks and benefits does not want definitive treatment, he may still be eligible for active surveillance.
5. Patients age > 18. Patients are typically offered AS if they are ≥ 60 years of age. However, if a man meets pathologic criteria and is < 60, he can be entered in AS if, after discussing risks and benefits, does not want definitive treatment.
6. Most patients will have PSA value ≤ 10 ng/ml. However, since PSA is prostate specific and not prostate cancer specific, many patients with elevated PSA levels > 10 ng/ml will not have prostate cancer, and PSA is elevated due to conditions such as BPH or inflammation. If a patient has a PSA value > 10 ng/ml, but still meets all pathologic criteria, he may still be eligible for active surveillance
Kundu, Shilajit DKundu, Shilajit D
  • Map it 201 E. Huron St.
    Chicago, IL
STU00059221
More Info

For more information on this study please contact us:

Kundu, Shilajit D 1-888-NU-STUDY
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and capecitabine, work in different ways to stop the…
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy alone is more effective then chemotherapy plus radiation therapy in treating rectal cancer. PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery.
Halverson, Amy LHalverson, Amy L
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01515787 STU00067473
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
The Study Evaluating Efficacy And Tolerability of Velipari…
The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with locally recurrent Breast Cancer not amenable to therapy with curative intent, or metastatic breast cancer and a documented (BRCA1) and (BRCA2) deleterious germline mutation.
Gradishar, William JGradishar, William J
NCT01506609 STU00068228
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary My…
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
Stein, Brady LeeStein, Brady Lee
NCT01423851 STU00068449
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cel…
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab together with bendamustine and bortezomib is more effective than rituximab and bendamustine, followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma. PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and lenalidomide in treating previously untreated older patients with mantle cell lymphoma.
Winter, Jane NormaWinter, Jane Norma
NCT01415752 STU00068608
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
The purpose of this study is to - compare Progression Free Survival (PFS) after treatment with …
The purpose of this study is to - compare Progression Free Survival (PFS) after treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, progressive (as determined by Response Evaluation Criteria in Solid Tumors [RECIST] Criteria), somatostatin receptor positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours). - compare the Objective Response Rate (ORR) between the two study arms - compare the Overall Survival (OS) between the two study arms - compare the Time to Tumour Progression (TTP) between the two study arms - evaluate the safety and tolerability of 177Lu-DOTA0-Tyr3-Octreotate - evaluate the health related quality of life (QoL) as measured by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-G.I.NET21 questionnaire - explore the correlation of toxicity outcomes and administered radiation doses corrected for body weight and body surface area - explore the correlation of clinical efficacy outcomes with the levels of the biomarkers Chromogranin-A (CgA) in the serum and 5-Hydroxyindoleacetic acid (5-HIAA) in the urine - evaluate dosimetry, pharmacokinetics (PK) and ECG in a subset of 20 patients - explore the correlation of clinical efficacy outcomes with OctreoScan® tumour uptake score - explore the correlation of clinical outcomes with serum levels of Alkaline Phosphatase (AP)
Benson III, Al BBenson III, Al B
NCT01578239 STU00065623
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with s…
This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.
Altman, Jessica KAltman, Jessica K
NCT01546038 STU00067903
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
The primary objective of this study is to evaluate the Overall Survival, Best Tumor…
The primary objective of this study is to evaluate the Overall Survival, Best Tumor Response Rate, Time to Intracranial Progression (radiographic), Time to Clinical Brain Metastasis Progression, safety, and tolerability of veliparib and Whole Brain Radiation Therapy in subjects with brain metastases from Non Small Cell Lung Cancer
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01657799 STU00068212
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Mild Cognitive Impairment in Breast Cancer Patients
The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain are…
The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain areas are related to the development of mild cognitive impairment as the results of these treatments. This study involves obtaining pictures of the brain’s size, shape and activity using a Magnetic Resonance Imaging (MRI) device, a machine that uses a powerful magnet to obtain this information without using any radiation. This procedure has been used safely with humans in many different studies. Your part in this study will last for 1 to 2 years.
Female breast cancer patients between 40-70 years old
Wang, LeiWang, Lei
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT01949376 STU00069634
More Info

For more information on this study please contact us:

Berger, Jessica M 312 503 4995
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II clinical trial is studying how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblas…
This phase II clinical trial is studying how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.
Frankfurt, OlgaFrankfurt, Olga
NCT01256398 STU00070681
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
This randomized phase III trial is studying combination chemotherapy in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy work in different …
This randomized phase III trial is studying combination chemotherapy in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01231906 STU00070869
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
This Phase II trial is being developed following the completion of a Phase I study of the combination of temsirolimus and sorafenib in 25 first-line therapy patients with advanced hepatocel…
This Phase II trial is being developed following the completion of a Phase I study of the combination of temsirolimus and sorafenib in 25 first-line therapy patients with advanced hepatocellular carcinoma (December 2009 through April 2012). The maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of temsirolimus is 10 mg IV weekly plus sorafenib 200 mg (oral, twice daily).
Kircher, SheetalKircher, Sheetal
NCT01687673 STU00071124
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant g…
The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas. The safety of these drug combinations will also be studied. The goal of this Phase II part of this clinical research study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01266031 STU00071570
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cell death. Vitamin D has been used …
The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colorectal cancer. In this research study, the investigators are comparing standard and higher dose Vitamin D treatment when given in combination with standard treatment for metastatic colorectal cancer. Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX) with bevacizumab.
Kircher, SheetalKircher, Sheetal
NCT01516216 STU00071588
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant gliom…
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma. The goal of Phase 2 of this study to learn if the combination of everolimus and sorafenib can help to control malignant glioma. The safety of this combination will also be studied in both phases.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01434602 STU00071721
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
Pro, BarbaraPro, Barbara
NCT01728805 STU00072232
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with metastatic kidney cancer who have no …
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with metastatic kidney cancer who have no evidence of disease after surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Sosman, JeffreySosman, Jeffrey
NCT01575548 STU00071950
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. T…
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
Frankfurt, OlgaFrankfurt, Olga
NCT01696084 STU00072848
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and the best dose of lenalidomide when given together with temsirolimus and to see how well it works in treating pat…
This phase I/II trial studies the side effects and the best dose of lenalidomide when given together with temsirolimus and to see how well it works in treating patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide may also stop the growth of Hodgkin lymphoma or non-Hodgkin lymphoma by blocking blood flow to the cancer. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide together with temsirolimus may kill more cancer cells.
Kaplan, JasonKaplan, Jason
NCT01076543 STU00073218
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymph…
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma. This study is for patients who have a type of lymphoma that expresses a tumor marker called CD30 and/or a type that is associated with the Epstein-Barr virus (EBV-related lymphoma) and who have not yet received any treatment for their cancer, except for dose-reduction or discontinuation (stoppage) of medications used to prevent rejection of transplanted organs (for those patients who have undergone transplantation). This study is investigating the combination of brentuximab vedotin and rituximab as a first treatment for lymphoma patients
Kaplan, JasonKaplan, Jason
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01805037 STU00072695
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
This study is for patients who have been diagnosed with soft tissue sarcoma that has spread (metastasized) or that is not eligible for removal by surgery. The purpose of this study i…
This study is for patients who have been diagnosed with soft tissue sarcoma that has spread (metastasized) or that is not eligible for removal by surgery. The purpose of this study is to determine how soft tissue sarcomas respond to treatment with an investigational drug called tivozanib. In some lab and clinical studies, tivozanib has been shown to interfere with the growth of some types of tumors. The study will also evaluate how safe the study treatment is by observing how many and what kind of adverse events (side effects) participants experience.
Agulnik, MarkAgulnik, Mark
NCT01782313 STU00073826
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of …
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This randomized phase III trial is studying two different methods of radiation and their side effects and comparing how well they work in treating endometrial and cervical cancer after surgery.
Donnelly, EricDonnelly, Eric
NCT01672892 STU00073668
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery
This randomized phase II trial studies how well cetuximab with or without tivantinib works in treating patients with head and neck cance…
This randomized phase II trial studies how well cetuximab with or without tivantinib works in treating patients with head and neck cancer that is recurrent, metastatic, or cannot be removed by surgery. Monoclonal antibodies, such as cetuximab, can interfere with tumor growth by blocking the ability of tumor cells to grow and spread. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cetuximab is more effective with or without tivantinib in treating patients with head and neck cancer.
Agulnik, MarkAgulnik, Mark
NCT01696955 STU00073973
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transpla…
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation
Kulik, Laura MKulik, Laura M
NCT01624285 STU00048134
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer
The purpose of this study is to determine whether or not the medication that blocks the effects of the hormone progesterone (CDB-4124 or Proellex) will decrease the growth rate of breast cancer cells as compared…
The purpose of this study is to determine whether or not the medication that blocks the effects of the hormone progesterone (CDB-4124 or Proellex) will decrease the growth rate of breast cancer cells as compared to a placebo. CDB-4124 (also called Proellex) is a medication that works against the hormone, progesterone. The researchers in this study would like to compare changes in breast cancer cells of women who have taken CDB-4124 prior to surgery to those from women who have taken a placebo pill prior to surgery.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT01800422 STU00074599
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as b…
This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet know whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma
Kumthekar, PriyaKumthekar, Priya
NCT01730950 STU00075529
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of …
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Matei, DanielaMatei, Daniela
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01853644 STU00073756
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
This partially randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in …
This partially randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of thyroid cancer by blocking blood flow to the tumor. It is not yet known whether cediranib maleate is more effective when given together with lenalidomide in treating thyroid cancer.
Agulnik, MarkAgulnik, Mark
NCT01208051 STU00078077
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in…
The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator.
Frankfurt, OlgaFrankfurt, Olga
NCT01742299 STU00078335
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with …
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person's own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them. It is not yet known whether giving vaccine therapy is more effective with or without bevacizumab in treating glioblastoma multiforme.
Bloch, OrinBloch, Orin
NCT01814813 STU00079456
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cyta…
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.
Altman, Jessica KAltman, Jessica K
NCT01802333 STU00079895
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the sy…
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the growth of new blood vessels; therefore it might stop tumor growth and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels.
Kumthekar, PriyaKumthekar, Priya
NCT01898130 STU00080404
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly dia…
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01790503 STU00079884
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
This partially randomized phase I/II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and how well they work in …
This partially randomized phase I/II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and how well they work in treating patients with IV head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective when given with or without veliparib in treating head and neck cancer.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01711541 STU00081215
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, …
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Flaum, LisaFlaum, Lisa
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01674140 STU00082264
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.
Kumthekar, PriyaKumthekar, Priya
NCT01800695 STU00084903
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion
This is a Phase 2, open label, multicenter, study evaluating the efficacy of ABT-199 in approximately 100 relapsed or refractory subjects with CLL harboring …
This is a Phase 2, open label, multicenter, study evaluating the efficacy of ABT-199 in approximately 100 relapsed or refractory subjects with CLL harboring 17p13 (TP53 locus) deletion.
Ma, ShuoMa, Shuo
NCT01889186 STU00083476
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cance…
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
Chae, Young KwangChae, Young Kwang
NCT01774578 STU00083862
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This Phase I trial studies the safety and efficacy of vaccine therapy in treating patients with previously untreated chronic lymphocytic leukemia. Liposome-based vaccines containin…
This Phase I trial studies the safety and efficacy of vaccine therapy in treating patients with previously untreated chronic lymphocytic leukemia. Liposome-based vaccines containing an extract of a person's cancer cells and the immunostimulant interleukin-2 may help the body to build an effective immune response to kill cancer cells.
Ma, ShuoMa, Shuo
NCT01976520 STU00083074
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer…
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer
Donnelly, EricDonnelly, Eric
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01872975 STU00083782
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCET…
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Pro, BarbaraPro, Barbara
NCT01712490 STU00083869
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells b…
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Benson III, Al BBenson III, Al B
NCT01841736 STU00083973
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide works in treati…
This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide works in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether rituximab and combination chemotherapy are more effective when given with or without lenalidomide in treating patients with diffuse large B cell lymphoma.
Kaplan, JasonKaplan, Jason
NCT01856192 STU00085928
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"
This multicenter, single- arm study will evaluate the efficacy and safety of MPDL3280A in patients with PD-L1-positi…
This multicenter, single- arm study will evaluate the efficacy and safety of MPDL3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer. Patients will receive MPDL3280A 1200 mg intravenously every 3 weeks for a maximum of 16 cycles (or 12 months, whichever occurs first) in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression. Patients who complete the initial treatment stage may be eligible fro MPDL3280A re-treatment upon subsequent disease progression during the follow-up period without intervening systemic anti-cancer therapy.
Mohindra, NishaMohindra, Nisha
NCT02031458 STU00087058
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
This study will compare two doses of pembrolizumab versus docetaxel in participants with non-small cell lung cancer (NSCLC) …
This study will compare two doses of pembrolizumab versus docetaxel in participants with non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-containing systemic therapy. Participants will be assigned randomly to receive either Low Dose or High Dose pembrolizumab every three weeks (Q3W), or docetaxel at 75 mg/m^2 Q3W. This study will use an adaptive trial design so that the total number of participants randomized will depend upon demonstration of sufficient objective responses at interim analysis. If the pembrolizumab Low Dose arm is closed, participants may receive pembrolizumab High Dose therapy.
Chae, Young KwangChae, Young Kwang
NCT01905657 STU00087871
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten …
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02048722 STU00087654
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either …
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values. The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).
Nieves-Neira, WilbertoNieves-Neira, Wilberto
NCT01847274 STU00087845
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally …
This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally administered combination of BYL719 and MEK162. This combination will be explored in adult patients with advanced CRC, esophageal cancer, pancreatic cancer, NSCLC, ovarian cancer, or other advanced solid tumors and in adult patients with AML or high risk and very high risk MDS, with documented RAS or BRAF mutations. Dose escalation will be guided by a Bayesian logistic regression model with overdose control. At MTD or RDE, four expansion arms will be opened in order to further assess the safety and preliminary activity of the combination of BYL719 and MEK162 in specific patient populations.
Chae, Young KwangChae, Young Kwang
NCT01449058 STU00089683
More Info

For more information on this study please contact us:

1-855-NU-STUDY
ANG1005 in Patients With Recurrent High-Grade Glioma
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokineti…
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.
Kumthekar, PriyaKumthekar, Priya
NCT01967810 STU00086859
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies
This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first …
This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population during dose escalation (Part A) will consist of adults previously diagnosed with any form of a solid tumor or lymphoma for which standard, curative, or life-prolonging treatment does not exist or is no longer effective. This first-in-human (FIH) study will include 2 dose expansion cohorts in refractory and/or relapsed CLL and DLBCL (Part B) following completion of dose escalation (Part A).
Kaplan, JasonKaplan, Jason
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02000934 STU00088167
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
The purpose of this study is to see whether a combination of two different drugs - trastuzumab-MCC-DM1 (T-DM1) and BYL719 is safe, and if it might be effective in treating …
The purpose of this study is to see whether a combination of two different drugs - trastuzumab-MCC-DM1 (T-DM1) and BYL719 is safe, and if it might be effective in treating metastatic breast cancer. T-DM1 is a type of drug that contains an antibody (trastuzumab) linked to chemotherapy. The antibody in T-DM1 targets a marker on breast cancer cells called HER2, which allows the drug to go directly to the cancer cells. The use of T-DM1 in this study is considered standard treatment for the type of cancer in this study. Participants in this study have already been treated with trastuzumab and chemotherapy in the past, and their cancer has gotten worse in spite of those treatments. BYL719 is an oral drug (taken by mouth) that the researchers think may help T-DM1 to work better.
Gradishar, William JGradishar, William J
NCT02038010 STU00087202
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
The purpose of this study is to determine the maximum tolerated dose and the safety profile of MEDI4736 in combination with dabrafenib and trametinib or with trametinib…
The purpose of this study is to determine the maximum tolerated dose and the safety profile of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone in subjects with metastatic or unresectable melanoma with BRAF-mutation positive or Wild Type BRAF, respectively.
Chandra, SunandanaChandra, Sunandana
NCT02027961 STU00088281
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to patients with recurrent GBM, whose tumors demonstrate FGFR amplification, translocation, or activating mutation.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01975701 STU00089428
More Info

For more information on this study please contact us:

1-888-NU-STUDY
An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS…
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Dinner, ShiraDinner, Shira
NCT02039726 STU00090667
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Epigenetic Markers of Bladder Cancer Progression
The purpose of this study is to better understand the expression of certain genes and genetic changes that occur in bladder tumors.
Male or female patients aged 40-89 identified to have a bladder lesion or mass concerning for urothelial carcinoma based on cystoscopy or imaging who are scheduled to undergo transurethral resection of bladder tumor (TURBT).
Meeks, Joshua JMeeks, Joshua J
STU00088853
More Info

For more information on this study please contact us:

Meeks, Joshua J 1-888-NU-STUDY
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
The purpose of this study is to find out what effects, good and/or bad, treatment with vemurafenib (also known as Zelboraf™) has on the patient and on leukemia. Specifically, the re…
The purpose of this study is to find out what effects, good and/or bad, treatment with vemurafenib (also known as Zelboraf™) has on the patient and on leukemia. Specifically, the researchers want to know how well vemurafenib eliminates leukemia from the blood.
Altman, Jessica KAltman, Jessica K
NCT01711632 STU00089215
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL). …
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
Ma, ShuoMa, Shuo
NCT01980628 STU00090706
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
This is a 3 arm Phase 3 study to evaluate the safety and…
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gradishar, William JGradishar, William J
NCT02032277 STU00091377
More Info

For more information on this study please contact us:

1-855-NU-STUDY
ANG1005 in HER2+ Breast Cancer Patients With Progressive/Recurrent Brain Metastases
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in HER2+ breast cancer patients with recurrent brain metastases.
Kumthekar, PriyaKumthekar, Priya
NCT02048059 STU00091395
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase I Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
The purpose of this Phase I, multi-center study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-221 in advanced hematologic malignancies that…
The purpose of this Phase I, multi-center study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-221 in advanced hematologic malignancies that harbor an IDH2 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-221 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where three cohorts of patients will receive AG-221 to further evaluate the safety, tolerability, and clinical activity of the MTD. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Altman, Jessica KAltman, Jessica K
NCT01915498 STU00091898
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study is to determine whether treatment with dovitinib (TKI258) demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic mali…
The purpose of this signal seeking study is to determine whether treatment with dovitinib (TKI258) demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Chae, Young KwangChae, Young Kwang
NCT01831726 STU00092203
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Selinexor (KPT-330) in Older Patients With Relapsed AML
This is a randomized, multicenter, open-label, Phase 2 study of the SINE Selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Patients age ≥ 60 years with relapsed…
This is a randomized, multicenter, open-label, Phase 2 study of the SINE Selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Patients age ≥ 60 years with relapsed/refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.
Frankfurt, OlgaFrankfurt, Olga
NCT02088541 STU00092397
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
This study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for…
This study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil. Primary outcomes data is disease free survival (the time from randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of Hepatitis C, problems related to wound healing, hernia repair within the first 12 months, hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant diabetes, hypertension, and hyperlipidemia.
Kulik, Laura MKulik, Laura M
NCT02081755 STU00083409
More Info

For more information on this study please contact us:

Bezler, Laura 312 694 0260
Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants
The purpose of this study is to study the relationships between obesity, hormones and menopausal status, and breast cancer. The researchers would like to study whether a type of nutritional inte…
The purpose of this study is to study the relationships between obesity, hormones and menopausal status, and breast cancer. The researchers would like to study whether a type of nutritional intervention, called a time-restricted diet or tRD, is easy to maintain using a smartphone application; the researchers also want to study the effect that a tRD has on weight control, hormones, and breast tissue. A tRD is a type of diet that requires people to restrict their daily eating to a specific time frame each day. The researchers think that this might be an effective and manageable way to control weight.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT02154984 STU00091568
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor…
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective when given alone or together with cetuximab in treating patients with head and neck cancer that has been removed by surgery. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for locally advanced head and neck cancer.
Mittal, Bharat BMittal, Bharat B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00956007 STU00091727
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)
The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied.…
The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied. The study doctor can explain how the study drugs are designed to work.
Raizer, Jeffrey JRaizer, Jeffrey J
NCT01931098 STU00092064
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malign…
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where three cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the MTD. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Altman, Jessica KAltman, Jessica K
NCT02074839 STU00092474
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
Agulnik, MarkAgulnik, Mark
NCT02049905 STU00092843
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This randomized phase III trial studies ibrutinib and rituximab to see how well they work compa…
This randomized phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether fludarabine phosphate, cyclophosphamide, and rituximab are more effective than ibrutinib and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ma, ShuoMa, Shuo
NCT02048813 STU00093033
More Info

For more information on this study please contact us:

1-855-NU-STUDY
B-WELL-Mom (Breathe-Wellbeing, Environment, Lifestyle, and Lung Function)
This NIH funded research study is to better understand how the lungs function during pregnancy and how the immune system responds to pregnancy. This study will help us to better understand why some women with asthma experience…
This NIH funded research study is to better understand how the lungs function during pregnancy and how the immune system responds to pregnancy. This study will help us to better understand why some women with asthma experience worsening of their symptoms while others improve. Because pregnancy affects lung function and immune response of all women, we are looking for both women with and without asthma to participate. The study consists of 4 clinic visits (1st, 2nd, and 3rd trimesters of pregnancy and 4 months postpartum), and an at-home diary.
-Pregnant women at least 18 years old.
-Less than 15 weeks pregnant with a single baby.
-Women with and without asthma are eligible to participate. -No diagnosis of Multiple Sclerosis, Lupus, Rheumatoid Arthritis, HIV, or Mixed Connective Tissue Disease.
Grobman, William AGrobman, William A
STU00093038
More Info

For more information on this study please contact us:

Wolfe, Kaitlin A 312 503 3248
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they…
This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab, can block cancer growth in difference ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet know whether rituximab with bendamustine hydrochloride is more effective than rituximab and ibrutinib or ibrutinib alone in treating chronic lymphocytic leukemia.
Ma, ShuoMa, Shuo
NCT01886872 STU00093727
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
Kumthekar, PriyaKumthekar, Priya
NCT02078648 STU00093962
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
Shahabi, ShohrehShahabi, Shohreh
NCT01844986 STU00094075
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel…
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel and carboplatin is more effective with or without metformin hydrochloride in treating endometrial cancer.
Shahabi, ShohrehShahabi, Shohreh
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02065687 STU00093932
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
This randomized phase II clinical trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma…
This randomized phase II clinical trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept may stop the growth of melanoma by blocking blood flow to the tumor. It is not yet known whether aldesleukin is more effective with or without ziv-aflibercept in treating melanoma.
Chandra, SunandanaChandra, Sunandana
NCT01258855 STU00094690
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopo…
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advanced primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate whether adding the drug Ruxolitinib will further aid in reducing pre-transplant spleen size, improve physical performance levels and reduce adverse events (side effects) related to the transplant. Ruxolitinib is a drug that is approved by the FDA for the treatment of patients with advanced forms of myelofibrosis. Using Ruxolitinib prior to stem cell transplantation is experimental.
Adekola, KehindeAdekola, Kehinde
NCT01790295 STU00092812
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide norm…
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these studies will be correlated with subjects' disease symptoms and response to their experimental treatment. The MPD-RC researchers are interested in studying molecules from the blood and bone marrow, the exact molecules changing over time with the investigators choosing only the most promising for investigation. The investigators are attempting to better understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is believed that further basic knowledge about these cancer cells as well as the effects of treatment will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. The MPD-RC is hoping to determine if a number of laboratory tests (biomarkers) will allow for the prediction of response in future patients to the treatment they would receive.
Adekola, KehindeAdekola, Kehinde
NCT00665067 STU00093364
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and ph…
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02048371 STU00094754
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Gliomas
This research study involves two investigational drugs, veledimex, an a…
This research study involves two investigational drugs, veledimex, an activator ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001). IL-12 is a protein that may improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of INXN-2001 given in combination with oral veledimex.
Inclusion Criteria: 1. Male or female subjects ≥ 18 and ≤ 75 years of age. 2. Histologically confirmed supratentorial glioblastoma or other WHO grade III or IV malignant glioma from archival tissue. 3. Evidence of tumor recurrence/progression by MRI (RANO criteria) post standard initial therapy. 4. Previous standard of care anti-tumor treatment including surgery and/or biopsy and chemoradiation. 5. Able to undergo standard MRI scans with contrast agent. 6. Karnofsky Performance Status ≥ 70. 7. Adequate bone marrow reserves and liver and kidney function. 8.Male and female subjects must agree to use a highly reliable method of birth control. Exclusion Criteria: 1. Radiotherapy within 4 weeks or less prior to starting first veledimex dose. 2. Subjects with clinically significant increased intracranial pressure or uncontrolled seizures. 3. Known immunosuppressive disease, autoimmune conditions, and /or chronic viral infections. 4. Use of systemic antibacterials, antifungals or antivirals for the treatment of acute clinically significant infection. 5. Use of enzyme-inducing anti-epileptic drugs (EIAED) within 7 days prior to the first dose of study drug. 6. Other concurrent clinically active malignant disease requiring treatment. 7. Nursing or pregnant females. 8. Prior exposure to veledimex. 9. Presence of any contra-indication for a neurosurgical procedure.
Lesniak, MaciejLesniak, Maciej
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02026271 STU00094296
More Info

For more information on this study please contact us:

Amidei, Christina 312 695 9124
ECOG 1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.
Purpose This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL). Overview …
Purpose This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL). Overview This study is for patients who have recently been diagnosed with a subtype of ALL that is known as BCR-ABL negative B-lineage ALL. Blinatumomab is a new antibody therapy that binds to B cells and recruits T cells to attack leukemia B cells. Patients will be randomized to receive chemotherapy what has traditionally been used to treat this sub-type of ALL alone or chemotherapy with blinatumomab . Studies are being done in ALL and other blood cancers with blinotumomab Blinatumomab has been effective in residual or relapsed B-cell ALL at destroying these specific cells. But it has not yet been proven helpful in combination with chemotherapy in newly diagnosed ALL. Description of Treatment There are several steps of treatment in this study. They are called induction, intensification, consolidation, and maintenance. In these study steps participants will be getting standard chemotherapy treatments that may or may not be combined with a new cancer drug called blinatumomab. Blinatumomab is a drug that is given as a continues infusion. The treatment schedule should be discussed with the study doctor.
Some of the eligibility criteria include:

- Participants in this study must have B lineage ALL that is Philadelphia chromosome and BCR/ABL negative. Please discuss this requirement with the study doctor.
- Participants must be 35-70 years old.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Dinner, ShiraDinner, Shira
  • Map it 201 E. Huron St.
    Chicago, IL
STU00093458
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
The Chimerix CMX001 Registry
The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other Double-stranded DNA viru…
The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other Double-stranded DNA virus associated events, s well as survival rates in subjects previously enrolled in selected clinical studies of CMX001. Each Registry participant will be followed for a period of approximately 3 years from their enrollment in the Registry.
Ison, Michael GIson, Michael G
NCT02167685 STU00095440
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye. Ca…
This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Chandra, SunandanaChandra, Sunandana
NCT01835145 STU00096579
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Ibrutinib With Rituximab in Previously Treated Adults With Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in subjects with previously treated Waldenstrom's Macroglobulinemia.
Ma, ShuoMa, Shuo
NCT02165397 STU00097388
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together w…
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with glioblastoma multiforme that has come back. Monoclonal antibodies, such as anti-endoglin monoclonal antibody TRC105 and bevacizumab, may find tumor cells and help kill them. Giving anti-endoglin monoclonal antibody TRC105 together with bevacizumab may be an effective treatment for glioblastoma multiforme.
Kumthekar, PriyaKumthekar, Priya
NCT01648348 STU00097918
More Info

For more information on this study please contact us:

1-855-NU-STUDY
BKM120 for Patients With PI3K-activated Tumors
The purpose of this signal seeking study is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Chae, Young KwangChae, Young Kwang
NCT01833169 STU00098066
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to describe the dose limiting toxicities (DLT) and define the maximum tolerated dose (MTD) of ASP2215 when combined wi…
The purpose of this study is to describe the dose limiting toxicities (DLT) and define the maximum tolerated dose (MTD) of ASP2215 when combined with cytarabine/idarubicin remission induction in a 7+3 schedule. Safety and tolerability of ASP2215 will also be evaluated. This study will also characterize the pharmacokinetics (PK) of ASP2215 when given in combination with cytarabine/idarubicin remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed acute myeloid leukemia as well as evaluate the effect of ASP2215 on the PK of cytarabine.
Altman, Jessica KAltman, Jessica K
NCT02236013 STU00098340
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety of orally administered ABT-199 combined with decitabine or azacitidine and the prelimina…
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety of orally administered ABT-199 combined with decitabine or azacitidine and the preliminary efficacy of one of these combinations.
Frankfurt, OlgaFrankfurt, Olga
NCT02203773 STU00098734
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
This randomized phase II-R/III tria…
This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving chemotherapy together with or without erlotinib hydrochloride and/or radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given with or without erlotinib hydrochloride and/or radiation therapy in treating pancreatic cancer.
Hayes, John PHayes, John P
NCT01013649 STU00099583
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity
We are recruiting people motivated to lose weight to participate in a 6 month weight loss intervention study. The purpose of this study is to see what combination of different weight loss program components is t…
We are recruiting people motivated to lose weight to participate in a 6 month weight loss intervention study. The purpose of this study is to see what combination of different weight loss program components is the most effective for overall weight loss. All participants will receive a personal coach who will communicate with them regularly over the telephone throughout the study. All participants must own a personal smartphone and be willing and able to record their food intake on a smartphone application that will be provided. Participants will be randomly assigned to 1 of 16 possible programs that may include a combination of the following weight loss program components: Coaching Calls, Text Messaging, Reports to Primary Care Physician, Buddy Training, Meal Replacement Recommendations. Participants are asked to attend a total of 5 in-person sessions throughout the course of the study, and all appointments will be held on Northwestern University's Chicago campus at 680 N. Lake Shore Drive. Chicago, IL 60611. Free parking vouchers will be provided for those who drive to in-person visits. This study DOES NOT involve medication/drugs.
You may be eligible to participate if you: Are between 18-60 years old; Will be living in the Chicagoland area for the next 6 months; Are NOT currently pregnant, trying to become pregnant, or breastfeeding; Do NOT have an unstable medical condition; Have an Android or iPhone smartphone; Are willing to track your lifestyle behaviors using a smartphone for 6-months
Spring, BonnieSpring, Bonnie
NCT01814072 STU00066546
More Info

For more information on this study please contact us:

Paluch, Amanda 773 234 6711
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction ch…
This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy. This drug blocks an enzyme that affects how the lymphocytes grow and survive. The investigators hope to learn how safe and effective ibrutinib is for treating patients with MCL after responding to induction chemotherapy.
Some of the eligibility criteria include:

- Participants must have mantel cell lymphoma.
- Participants must have had initial treatment (at least 4 cycles) for their lymphoma and their disease got better (partial or complete response).
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kaplan, JasonKaplan, Jason
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02242097 STU00098385
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the e…
This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in approximately 40 subjects with relapsed or refractory CLL after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.
Ma, ShuoMa, Shuo
NCT02141282 STU00100071
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lym…
The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).
Some of the eligibility criteria include:

- Participants must have PTCL.
- Participants may not have had prior systemic treatment for their PTCL. Treatment with corticosteroids is allowed. Please discuss all treatments with the study doctor.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Pro, BarbaraPro, Barbara
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02232516 STU00097620
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel a…
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy. The purpose of this study is to evaluate the effectiveness and safety of the combination of nab-paclitaxel and gemcitabine. The effectiveness will be determined by improvement in the length of time during and after treatment, that the CCA does not get worse.
Benson III, Al BBenson III, Al B
NCT02181634 STU00100012
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breas…
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally may be safer and have fewer side effects than oral administration.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02314156 STU00100531
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Development of a Kidney Cancer Patient Outcomes Database
Purpose This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life. Overview A registry is a repository (database) of information about a group of people who …
Purpose This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life. Overview A registry is a repository (database) of information about a group of people who share a common characteristic - in this case, kidney cancer. MYQOL registry participants enter information about their disease, treatment, symptoms, health status, and quality of life into an on-line, password-protected database on a regularly scheduled basis. Participants can use the registry to track many of their symptoms and their health status over time and to compare themselves (anonymously) with other groups of people (for example, how their level of fatigue compares with the average level of fatigue reported by other participants in the registry). Participants can also choose to share relevant information about themselves (from the registry) with their health care provider(s), by printing copies of their completed forms. Registry participants will be offered opportunities to join in other research studies when available. Description of Treatment Participants in this study will be asked to do the following for a 1-year trial period: 1) enroll in the on-line registry; 2) complete questionnaires about their health and treatment every 3 months ; and 3) be willing to have MYQOL researchers contact them confidentially about participating in other research studies. This does not mean that participants are obligated to participate in future research studies; only that they agree to be contacted.
Some of the eligibility criteria include:

- Participants must have a kidney cancer diagnosis.
- Participants must be 18 or older.
- Participants must be able to read English well enough to complete questionnaires.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Cella, DavidCella, David
  • Map it 201 E. Huron St.
    Chicago, IL
STU00070200
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study …
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
Chae, Young KwangChae, Young Kwang
NCT02002689 STU00100530
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients…
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation.
Mohindra, NishaMohindra, Nisha
NCT02201992 STU00102000
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
The goal of this study is to develop a new combined treatment to help individuals with clinical depression to quit smoking. Participants will receive one of four treatments: 1) Standard behavior therapy + placebo; 2) Beh…
The goal of this study is to develop a new combined treatment to help individuals with clinical depression to quit smoking. Participants will receive one of four treatments: 1) Standard behavior therapy + placebo; 2) Behavioral activation for smoking cessation + placebo; 3) Standard behavior therapy + varenicline (Chantix); or 4) Behavioral activation for smoking cessation + varenicline (Chantix).
1. Adult (18 years of age or older) daily cigarette smokers (1+ cigarettes per day)
2. Lifetime history of clinical depression (Major Depressive Disorder)
Hitsman, Brian LHitsman, Brian L
NCT02378714 STU00100303
More Info

For more information on this study please contact us:

Reyes, Celine 1 877 236 7487
Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed By Surgery
This randomized phase III trial compares the effects of gemcitabine hydrochloride and cisplatin with or without radiation t…
This randomized phase III trial compares the effects of gemcitabine hydrochloride and cisplatin with or without radiation therapy to find out which one is better in treating patients with liver cancer that has not spread to nearby lymph nodes or to other parts of the body and cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. It is not yet known whether giving gemcitabine hydrochloride and cisplatin is better with or without radiation therapy in treating patients with liver cancer that cannot be removed by surgery.
Hayes, John PHayes, John P
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02200042 STU00102844
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 1 Study of MEDI6383 in Adult Subjects With Select Advanced Solid Tumors
To evaluate the tolerability of MEDI6383 in adult subjects with recurrent or metastatic solid tumors.
Chae, Young KwangChae, Young Kwang
NCT02221960 STU00103559
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations fo…
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study "Master Protocol". The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a "non-match" sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02154490 STU00100140
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
The purpose of this signal seeking study is to determine whether treatment with ceritinib demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic m…
The purpose of this signal seeking study is to determine whether treatment with ceritinib demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Chae, Young KwangChae, Young Kwang
NCT02186821 STU00103423
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib hydrochlo…
This randomized phase II/III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02180867 STU00105700
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant fu…
The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.
Chae, Young KwangChae, Young Kwang
NCT02160041 STU00104815
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Background: - Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox bin…
Background: - Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase III multicenter trial designed to confirm these results. Objectives: - To see how effective moxetumomab pasudotox is at destroying hairy cell leukemia tumor cells and producing lasting complete remissions. Eligibility: - Individuals at least 18 years of age who have hairy cell leukemia that has not responded to or relapsed at least twice after standard therapy. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and heart and lung function tests will also be performed. - Participants will have 28-day cycles of treatment. They will receive the study drug on days 1, 3, and 5 of every cycle. Each dose will take about 30 minutes. - Treatment will be monitored with frequent blood and urine tests and imaging studies. - The study will focus on the results from the first 6 months of treatment. However, participants will continue to take the study drug for as long as it is effective and the side effects are not severe. - After stopping the study drug, participants will have frequent follow-up visits to monitor the outcome of the treatment.
Dinner, ShiraDinner, Shira
NCT01829711 STU00105706
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery…
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Mohindra, NishaMohindra, Nisha
NCT02194738 STU00200150
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)
Randomized two-arm, multicenter, open-label Phase 2b study of 2 doses of selinexor (KPT-330) high with low dose dexamethasone in patients with relapsed/refractory de novo DLBC…
Randomized two-arm, multicenter, open-label Phase 2b study of 2 doses of selinexor (KPT-330) high with low dose dexamethasone in patients with relapsed/refractory de novo DLBCL who have no therapeutic options of demonstrated clinical benefit.
Kaplan, JasonKaplan, Jason
NCT02227251 STU00200116
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Phase IIB TL + YCWP + DC in Melanoma
The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants. As opposed to testing an "off the…
The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants. As opposed to testing an "off the shelf" vaccine that might be able to treat a subset of patients, our approach has been personalized to the patient and applicable to all patients. Our vaccine approach consists of harnessing the most potent antigen presenting cell in the body - the dendritic cell (DC) - together with the full repertoire of tumor antigens from an individual's cancer. We have conducted phase I and II studies using an autologous DC-tumor cell fusion technique that has now been simplified into a DC-tumor cell lysate vaccine. The autologous tumor lysate (TL) is loaded into yeast cell wall particles (YCWP) that are naturally and efficiently taken up into the patient's DC. These autologous tumor lysate, particle-loaded, DC (TLPLDC) are injected intradermally (ID) monthly x 3 followed by boosters at 6, 12, and 18 months.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02301611 STU00200122
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or c…
This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or transmit tumor killing molecules to them. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel.
Mittal, Bharat BMittal, Bharat B
NCT01810913 STU00200314
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
There are two study questions the investigators are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA)…
There are two study questions the investigators are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and flurouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.
Mittal, Bharat BMittal, Bharat B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02135042 STU00200330
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this dr…
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02357810 STU00200112
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Purpose The purpose of this study is to compare any good and bad effects patients may have when treated with the st…
Purpose The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug). Overview This study is for patients with early stage non-small cell lung cancer that was surgically removed and may have been treated with chemotherapy and/or radiation. The tumor removed has a mutation of a gene called EGFR (Epidermal Growth Factor Receptor). Researchers are trying to find out if this mutation could help doctors make decisions about which type of treatment is best for people with this type of cancer. People not in a research study are usually not treated with anything after they finish their chemotherapy although some of them may receive radiation therapy. Description of Treatment This study has two study groups. Group 1 will get the study drug called erlotinib. The erlotinib will be taken once a day. Group 2 will get the placebo, which looks just like the erlotinib but does not have any active ingredients. The placebo will be taken once a day.
Some of the eligibility criteria include:

- Participants must have NSCLC.
- Participants must EGFR mutant and ALK rearrangement, which is detected by genetic testing performed through the study doctor's office.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Mohindra, NishaMohindra, Nisha
  • Map it 201 E. Huron St.
    Chicago, IL
STU00200145
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Ex vivo interactions between high-density-like nanoparticles and human blood
This research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Pr…
This research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Prior to initiating large-scale in vivo animal and human studies it is imperative that we obtain an in-depth knowledge of the interaction of the HDL-NPs with human blood cells using safe ex vivo experiments.
Healthy, non-pregnant adult (age >18-75 years) volunteers.
Thaxton, Colby SThaxton, Colby S
  • Map it 201 E. Huron St.
    Chicago, IL
STU00200368
More Info

For more information on this study please contact us:

Thaxton, Colby S 312 503 1826
Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC
This is a phase I/II study for previously untreated patients with advanced NSCLC. The study will take place in two phases. First, a cohort of twelve participants will be enrolled in phase I and will be treated with carbopla…
This is a phase I/II study for previously untreated patients with advanced NSCLC. The study will take place in two phases. First, a cohort of twelve participants will be enrolled in phase I and will be treated with carboplatin, nab-paclitaxel and MK-3475 and evaluated for safety and tolerability after 2 cycles of therapy. If needed, a second cohort of twelve participants will be enrolled. Following successful completion of the dose-finding/safety run-in cohort, the study will proceed to phase II. Mandatory pre-treatment tumor biopsies will be obtained prior to initiating treatment for all participants (only if adequate archived samples are unavailable). Mandatory tumor biopsies will be obtained in the phase II part of the study after 4 cycles or at the time of progression, whichever comes first. The phase II part of the study is a single arm study. All participants will be treated with carboplatin, nab-paclitaxel, and MK-3475 at the recommended phase II dose (RP2D) in 21-day cycles for up to 4 cycles. Participants will be evaluated for response every 2 cycles (6 weeks). For participants without progression of disease after Cycle 4, MK-3475 will continue every 3 weeks for up to 2 years or until unacceptable toxicity.
Mohindra, NishaMohindra, Nisha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02382406 STU00105339
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel or pemetrexed is more effective than docetaxel or pemetrexed alone in regards to PFS…
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel or pemetrexed is more effective than docetaxel or pemetrexed alone in regards to PFS in patients with heregulin-positive NSCLC.
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02387216 STU00200295
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studie…
The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied. Each participant will complete two 21-day cycles in a fixed order. Participants who complete Cycle 2 may continue to receive olaratumab + doxorubicin for an additional six 21-day cycles and then may receive olaratumab alone until discontinuation criteria are met. Screening is required within 21 days prior to first dose.
Agulnik, MarkAgulnik, Mark
NCT02326025 STU00200062
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This randomized phase II/III trial studies how well temozolomide and veliparib work and compare them to temozolomide alone in treating patients with newly diagnosed glioblastoma …
This randomized phase II/III trial studies how well temozolomide and veliparib work and compare them to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.
Kumthekar, PriyaKumthekar, Priya
NCT02152982 STU00200312
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light therapy in patients with cutaneous T-cell lymphoma.
Must be 18 years of age or older, with a clinical diagnosis of Cutaneous T- Cell Lymphoma, Myucosis Fungoides, Stage IA. Stage IB, or Stage IIA, and willing to refrain from sunbathing for duration of the study.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02448381 STU00200530
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
Observational US Study Assessing Outcomes, Treatment Patterns, AEs, QOL in MF-CTCL Patients and Treated With Valchlor
The purpose of this study is to better understand: the use of Valchlor®; the disease of MF-CTCL; the health outcomes in patients treated with Valchlor® under care by your doctor.
Adult patients currently being treated with Valchlor®, for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and able to sign an informed consent form without assistant from others.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02296164 STU00200362
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, ph…
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab or tremelimumab alone in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck.
Agulnik, MarkAgulnik, Mark
NCT02262741 STU00200513
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combinat…
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short). This is a type of study called a phase I/II trial. In the phase I part, the dose of the study drug (ixazomib) will be adjusted (either up or down) to find the maximum (highest) dose that does not cause excessive (too many) harmful side effects. In the phase II part, this dose of ixazomib will be given at the maximum safe dose found in phase I. In both phase I and II, DA-EPOCH-R will be adjusted between cycles depending on how blood cell levels are affected between cycles. Ixazomib is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA). DA-EPOCH-R is a combination chemotherapy treatment developed over the last 14-15 years, and each of the drugs in this regimen is FDA-approved and considered part of the standard of care.
Some of the eligibility criteria include:

- Participants must have diffuse large B-cell lymphoma (DLBCL) or other aggressive B-cell lymphoma that has an MYC-rearrangement. This is determined with special laboratory testing.
- Participants may not have had more than one prior cycle of chemoimmunotherapy for their lymphoma. All treatments should be discussed with the study doctor.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Pro, BarbaraPro, Barbara
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02481310 STU00200596
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzum…
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients who have received prior treatment with rastuzumab any setting and who have either progressed or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with anthracycline in any setting.
Flaum, LisaFlaum, Lisa
NCT02213744 STU00200503
More Info

For more information on this study please contact us:

1-888-NU-STUDY
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio…
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT02352883 STU00200436
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
The purpose of this study is to evaluate the safety of alisertib and its effect, bad and/or good, on acute megakaryoblastic leukemia (AMKL) or myelofibrosis (MF). The study…
The purpose of this study is to evaluate the safety of alisertib and its effect, bad and/or good, on acute megakaryoblastic leukemia (AMKL) or myelofibrosis (MF). The study drug, alisertib, is an investigational drug. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Alisertib has shown evidence in the lab that it may have an effect on a type of cell that produces platelets. This cell is called a megakaryocyte and it is known to be defective (doesn't work well) in both AMKL and MF.
Some of the eligibility criteria include:

- Participants must be 18 or older.
- Participants must have an estimated life expectancy of at least 6 months.
- Participants must have a confirmed diagnosis of one of the following (as defined by the World Health Organization criteria):

a. Relapsed/refractory acute megakaryoblastic leukemia (AMKL)

b. Myelofibrosis (MF), including primary and post-essential/post- polycythemic myelofibrosis

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Stein, Brady LeeStein, Brady Lee
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02530619 STU00200682
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane …
This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating postmenopausal patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective with or without entinostat in treating breast cancer.
Gradishar, William JGradishar, William J
NCT02115282 STU00200791
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received at least three previo…
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received at least three previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.
Nieves-Neira, WilbertoNieves-Neira, Wilberto
NCT02354586 STU00200818
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer
Pembrolizumab alone and in combination with ACP-196 in subjects with advanced non-small cell lung cancer.
Mohindra, NishaMohindra, Nisha
NCT02448303 STU00200814
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
This phase II trial studies how well nivolumab works in treating patients with squamous cell carcinoma of the anal canal that has not responded to previous treatment (refractory) a…
This phase II trial studies how well nivolumab works in treating patients with squamous cell carcinoma of the anal canal that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Kircher, SheetalKircher, Sheetal
NCT02314169 STU00201069
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may stop …
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the proteins needed for cell growth.
Agulnik, MarkAgulnik, Mark
NCT02066181 STU00201073
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Treating verbal memory deficits following chemotherapy for breast cancer
This is a treatment study testing a computerized therapy used at home to help with memory for words and to help with slowed mental processing speed. The study takes place over a 6 week period and there is a one-month follow ass…
This is a treatment study testing a computerized therapy used at home to help with memory for words and to help with slowed mental processing speed. The study takes place over a 6 week period and there is a one-month follow assessment after that. Participants will be randomized to receive treatment right away or will be given the option to receive treatment after 6 weeks.
Women between the ages of 65 and 90 years who have had chemotherapy treatment for early stage breast cancer. Ineligible if breast cancer diagnosis more than one time or any history of other cancer.
Cherney, Leora RCherney, Leora R
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00200767
More Info

For more information on this study please contact us:

Diane F. Morean, Ph.D. F. 847 644 2594
Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation
One in eight women will develop breast cancer in her lifetime, and many of these women undergo mastectomy followed by breast reconstruction by insertion of a tissue expander below the pectoralis major muscle. Wo…
One in eight women will develop breast cancer in her lifetime, and many of these women undergo mastectomy followed by breast reconstruction by insertion of a tissue expander below the pectoralis major muscle. Women undergoing breast reconstruction have been shown to have a significantly higher level of acute postoperative pain and postoperative narcotic requirement compared to women who undergo mastectomy alone without reconstruction. In addition to the inherently worthwhile end of providing patient comfort in the immediate postoperative period, decreased narcotic use carries with it the potential benefit of decreasing the incidence of other adverse effects such as nausea, vomiting, allergic reaction, and respiratory depression. Importantly, the intensity of pain in the immediate postoperative period has been implicated as an important factor predisposing patients to the development of chronic postoperative pain. Chronic pain following mastectomy is a significant and disabling problem, affecting up to 49% of patients in some series. Though breast reconstruction has been shown not to be an independent predictor of the development of chronic breast pain, improved control of acute pain in the immediate postoperative period carries significant promise in decreasing the incidence of this disabling condition for all breast cancer survivors treated with mastectomy. In addition, improving management of acute postoperative pain can shorten hospital stay, expedite return to daily normal activities and increase patient satisfaction. A variety of other adjuncts for pain control have been attempted in studies of variable methodological rigor, including injection of botulinum toxin into the pectoralis muscle, indwelling pain catheters, paravertebral blocks under ultrasound guidance, or simple irrigation of the general area of dissection during breast surgery with a solution containing local anesthestic. While each of these adjuncts has demonstrated some success, none has been widely adopted. Problems with these methods include cost, risk of adverse events, as well as anatomically incomplete or non-selective application. During mastectomy all breast tissue is removed, leaving the patient with denervated skin flaps. For breast reconstruction, a tissue expander is placed in a subpectoral pocket dissected between the pectoralis major and minor muscles. At the end of the procedure the pectoralis major muscle is placed under variable degree of tension depending on the amount of fluid placed inside the expander. This muscle stretch believed to be at least partially responsible for postoperative pain. In addition cut nerve endings in the superficial fascia likely contribute as well. The anatomy of nerves supplying the breast and involved muscles are well-described in rigorous cadaver studies. In this study we hypothesize that performing a block of the intercostal nerves responsible for innervating the breast tissue and skin and the pectoral nerves innervating the pectoralis major muscle should optimize immediate postoperative pain control in this patient population. Of adjuncts described in the literature, paravertebral blocks are the most anatomically targeted, but drawbacks include the need for a separate procedure preoperatively while the patient is awake by an anesthesiologist with facility performing these blocks as well as the risk of pneumothorax. Advantages of our proposed method include lack of pain as the patient is asleep, easy and speed of application, a decreased risk of pneumothorax as the injections are under direct visualization, as well as a decrease in cost and improved efficiency as the only a single provider (i.e. the operative surgeon) is required. Precedent for our technique has been described in the context of breast augmentation and breast lift, with a favorable safety profile and providing adequate analgesia to perform these procedures without the use of a general anesthetic.
Alghoul, MohammedAlghoul, Mohammed
NCT02525718 STU00200903
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in parti…
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC). ED SCLC is defined herein as any SCLC except a disease confined to the hemithorax of origin, with or without the involvement of regional lymph nodes, including ipsilateral and contralateral mediastinal, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular nodes
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02289690 STU00200750
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
ECOG-ACRIN 1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Purpose The main purpose of this study is to compare the usual approach (i.e. capecitab…
Purpose The main purpose of this study is to compare the usual approach (i.e. capecitabine), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (using the drug cisplatin or carboplatin), after surgery - in patients with triple negative breast cancer with residual basal-like disease who have received neoadjuvant chemotherapy. Overview Platinum agents (cisplatin or carboplatin) are already FDA-approved to be used in patients with stage IV breast cancers, but are usually not used in patients with early forms of breast cancer. The use of a platinum-based chemotherapy could prevent the cancer from returning (metastatic recurrence), but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. Description of Treatment Study participants will be randomly assigned by chance (like the flip of a coin) to one of the two study groups. Group 2 will get a platinum-based chemotherapy treatment for 12 weeks. Participants will receive a 30-minute intravenous infusion of either cisplatin or carboplatin once, every 3 weeks, for 4 doses (total of 12 weeks). Group 3 will get capecitabine treatment for 18 weeks. Participants will take the capecitabine pills twice a day for 2 weeks and then get one week off (called a cycle). There will be six cycles. After finishing treatment, all participants will be followed for about 10 years (every 3 months for the first 2 years from study entry, every 6 months if they are 2-5 years from study entry, every 12 months if they are 5-10 years from study entry).
Some of the eligibility criteria include:

- Participants must have early stage breast cancer.
- Participants must have triple negative breast cancer (ER-, PR- and HER2-).
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Flaum, LisaFlaum, Lisa
  • Map it 201 E. Huron St.
    Chicago, IL
STU00201173
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
This is a study for participants with advanced gastric or gastroe…
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The primary study hypotheses are that pembrolizumab prolongs progression free survival (PFS) and overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.
Benson III, Al BBenson III, Al B
NCT02370498 STU00200986
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase 1 Combination Study of MM-151 and MM-121
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121 at varying dose levels.
Chae, Young KwangChae, Young Kwang
NCT02538627 STU00201049
More Info

For more information on this study please contact us:

1-888-NU-STUDY
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors. …
The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors.
Benson III, Al BBenson III, Al B
NCT01916447 STU00201281
More Info

For more information on this study please contact us:

1-855-NU-STUDY
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
The main purpose of this study is to determine the anti-tumor activity of MEDI4736 in combination with tremelimumab in patients with metastatic HER2-negative breast cancer. Both MEDI4736…
The main purpose of this study is to determine the anti-tumor activity of MEDI4736 in combination with tremelimumab in patients with metastatic HER2-negative breast cancer. Both MEDI4736 and tremelimumab are antibodies (proteins used by the immune system to fight infections and cancers). MEDI4736 attaches to a protein in tumors called PD-L1. It may prevent cancer growth by helping certain blood cells of the immune system get rid of the tumor. Tremelimumab stimulates (wakes up) the immune system to attack the tumor by inhibiting a protein molecule called CTLA-4 on immune cells. Combining the actions of these drugs may result in better treatment options for patients with breast cancer.
Cristofanilli, MassimoCristofanilli, Massimo
NCT02536794 STU00200984
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
This study will examine the safety and efficacy of pertuzumab in combination with high-dose …
This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
Kumthekar, PriyaKumthekar, Priya
NCT02536339 STU00201462
More Info

For more information on this study please contact us:

1-888-NU-STUDY
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This is a study of INCB054329 given to patients with advanced malignancies that will be conducted in three treatment groups. Each treatment group will have two parts; a dose escalation (P…
This is a study of INCB054329 given to patients with advanced malignancies that will be conducted in three treatment groups. Each treatment group will have two parts; a dose escalation (Part 1) and an expansion (Part 2).
Kaplan, JasonKaplan, Jason
NCT02431260 STU00201341
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors, including gliomas, that harb…
This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors, including gliomas, that harbor an IDH1 and/or IDH2 mutation.
Altman, Jessica KAltman, Jessica K
NCT02481154 STU00201350
More Info

For more information on this study please contact us:

1-855-NU-STUDY
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
This is a study of INCB052793 given to patients with advanced malignancies that will be conducted in two phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy). Each …
This is a study of INCB052793 given to patients with advanced malignancies that will be conducted in two phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy). Each study phase will have two parts; a dose escalation (Part 1) and an expansion (Part 2).
Kaplan, JasonKaplan, Jason
NCT02265510 STU00201436
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
This single-arm, multicenter Phase 2 trial will treat adult patients who have relapsed or refractory B-ALL with an infusion of the patient's own T cells that have been geneticall…
This single-arm, multicenter Phase 2 trial will treat adult patients who have relapsed or refractory B-ALL with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) that will bind to leukemia cells that express the CD19 protein on the cell surface. The study will determine if these modified T cells (called JCAR015) help the body's immune system eliminate leukemia cells. The trial will also study the safety of treatment with JCAR015, how long JCAR015 cells stay in the patient's body, the extent to which JCAR015 eliminates minimal residual disease, and the impact of this treatment on survival.
Dinner, ShiraDinner, Shira
NCT02535364 STU00200524
More Info

For more information on this study please contact us:

1-855-NU-STUDY
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis.…
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will remain on-study until study completion, which will occur when all primary endpoint events (all-cause mortality or cardiac hospitalizations) have been reached.
Singhal, SeemaSinghal, Seema
NCT02312206 STU00201418
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with adva…
This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Participants will be randomly assigned to one of the 3 treatment arms of the study: pembrolizumab as monotherapy, or pembrolizumab + cisplatin + 5-fluorouracil (5-FU) or capecitabine, or placebo + cisplatin + 5-FU or capecitabine. The primary hypothesis is that pembrolizumab provides a clinically meaningful progression free and/or overall survival.
Benson III, Al BBenson III, Al B
NCT02494583 STU00201509
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
The purpose of this research study is to see if Atorvastatin(Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in women receiving adjuvant anthracycline-based chemotherapy…
The purpose of this research study is to see if Atorvastatin(Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in women receiving adjuvant anthracycline-based chemotherapy for breast cancer.
Lee, Daniel CLee, Daniel C
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01988571 STU00201665
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas [Transsphenoidal Extent of Resection Study – TRANSSPHER Study]
Endonasal transsphenoidal removal of…
Endonasal transsphenoidal removal of a pituitary tumor is a unique procedure and there is little information comparing the surgical techniques. The purpose of this research is to compare surgical techniques in patients with nonfunctioning pituitary adenomas (tumors that do not change hormone levels in patients). This is an observational, data collection study, which means there will be no experimental procedures or experimental medicines. Your participation in this study has no effect on the type of surgery you will have.
Adult patients with suspected nonfunctional pituitary macroadenomas who have planned transsphenoidal surgery.
Inclusion Criteria
-Patients with suspected nonfunctioning pituitary macroadenomas (≥ 1 cm) with planned transsphenoidal surgery
-Adults (age 18-80 years)
-Medically stable for surgery
-Reasonable expectation that patient will complete study and be available for follow-up assessments
*Patients who have had prior surgery are eligible for the study.
Exclusion Criteria
-Pregnant women
-Patients with suspected functioning pituitary adenoma
-Unable to obtain MRI of the pituitary
-Pituitary apoplexy
Chandler, James PChandler, James P
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02357498 STU00200458
More Info

For more information on this study please contact us:

Amidei, Christina 312 695 9124
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares …
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating limited metastatic breast cancer.
Strauss, Jonathan BStrauss, Jonathan B
NCT02364557 STU00201769
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
This randomized phase III trial studies how well initial treatment with ipilimumab and nivolum…
This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as v-raf murine sarcoma viral oncogene homolog B V600 (BRAFV600) and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02224781 STU00201842
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Genomic Medicine at Northwestern: Discovery and Implementation in the eMERGE Network
We are studying how patients and physicians use and value genetic information that resides in the electronic medical record. We plan to recruit and return information on over 100 genes to 3,000 Northwestern patients…
We are studying how patients and physicians use and value genetic information that resides in the electronic medical record. We plan to recruit and return information on over 100 genes to 3,000 Northwestern patients. Most of the genes being analyzed as part of this study have been linked to the development of a disease or condition, such as certain inherited cancers, certain types of inherited heart-related condition, and how our bodies respond to certain medications. There will also be some genes studied where the usefulness still being determined. Only results determined to potentially affect decisions that you and your physician(s) may make regarding your health care management will be placed in the electronic health record (EHR) for use by you and your Northwestern physicians. To participate, individuals need to be over 18 years of age, see a Northwestern physician, sign a consent form and donate approximately 1 table spoon of blood. Participants will also complete a baseline survey, will be given the option to be interviewed after receiving their results, and the option to participate in the NUgene Project, a genetic biobanking project designed to collect and store genetic and health information and provide those samples to researchers studying the genetics of common conditions such as diabetes, cancer, and heart disease.
Any Northwestern Medicine Patient who is 18 years of age or older.
Smith, Maureen ESmith, Maureen E
STU00201671
More Info

For more information on this study please contact us:

Study Coordinator 312 695 0700
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after …
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route Arm), and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for each Arm separately, in subjects with refractory ovarian cancer and recurrent malignant ascites. In both Arms, the plasma pharmacokinetics (PK) of BAX69 will be characterized, and pharmacodynamics (PD) markers will be explored in plasma and ascites. Two expansion cohorts will further assess the tolerability of the RP2D and explore clinical signs of efficacy.
Chae, Young KwangChae, Young Kwang
NCT02540356 STU00201544
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Phase II Trial of HM61713 (BI 1482694) for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung c…
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Chae, Young KwangChae, Young Kwang
NCT02485652 STU00201545
More Info

For more information on this study please contact us:

1-855-NU-STUDY
(CIRB) NRG CC001: A Randomized, Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Purpose To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole…
Purpose To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation can decrease the risk of cognitive side effects after radiation therapy to the brain to using the usual whole-brain radiation plus memantine (a drug that can also reduce cognitive side effects of brain radiation). Overview The hippocampus is important for memory formation, and rarely is involved by metastatic brain lesions. It is hoped that avoidance of the hippocampus with radiation will decrease the chance of cognitive side effects. However it is possible hippocampal avoidance could have no impact on cognitive side effects and could be associated with lower rates of disease control. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. Description of Treatment Group 1 will get the usual whole-brain radiation therapy plus memantine. Group 2 (investigational or study group) will get whole-brain radiation therapy using the hippocampal avoidance technique plus memantine.
Some of the eligibility criteria include:

- Participants must be 18 years of age or older.
- Participants must have pathologically (histologically or cytologically) proven diagnosis of solid tumor malignancy within 5 years prior to registration

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kruser, TimothyKruser, Timothy
  • Map it 201 E. Huron St.
    Chicago, IL
STU00201864
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Iron Deficiency and FGF23 Regulation in Chronic Kidney Disease and Heart Failure
Our research group is currently conducting a 6-week iron deficiency anemia study on healthy individuals, individuals with CKD, and individuals with CHF to find out if treating iron deficiency anemia with intravenous iro…
Our research group is currently conducting a 6-week iron deficiency anemia study on healthy individuals, individuals with CKD, and individuals with CHF to find out if treating iron deficiency anemia with intravenous iron sucrose therapy can safely and successfully lower FGF23 levels. Iron sucrose has been shown to lower FGF23 in animal models. The short term effects of iron sucrose on FGF23 levels in CKD and CHF are not known. We are conducting this research study to understand the effects of intravenous iron sucrose therapy on blood levels of FGF23 in iron deficiency anemia in healthy individuals, individuals with CHF, individuals with CKD, and individuals with CKD and CHF. The information gained from this study could be used to improve the health of patients with iron deficiency anemia and disease of the kidneys and heart.
Mehta, RupalMehta, Rupal
  • Map it 633 N. St. Clair St.
    Chicago , IL
NCT03106298 STU00201742
More Info

For more information on this study please contact us:

Hodakowski, Alexander 312 503 3901
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Pazopanib is FDA approved as a second line and beyond treatment for metastatic soft tissue sarcoma. There is a population of elderly and debi…
Pazopanib is FDA approved as a second line and beyond treatment for metastatic soft tissue sarcoma. There is a population of elderly and debilitated soft tissue sarcoma patients that are not fit for standard first line chemotherapy that is doxorubicin based. As pazopanib is well tolerated with minimal side effects, the investigators propose a phase II study to evaluate pazopanib as a first-line agent in patients with non-resectable or metastatic disease who are not candidates for cytotoxic chemotherapy.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02300545 STU00201925
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement and/or has spread to other parts of th…
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement and/or has spread to other parts of the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Agulnik, MarkAgulnik, Mark
NCT02339558 STU00201682
More Info

For more information on this study please contact us:

1-888-NU-STUDY
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally. Screening of…
This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. Eligible subjects will be enrolled into one of three cohorts based on tumor type: - Cohort 1: MRT, RTK, ATRT, or selected tumors with rhabdoid features - Cohort 2: Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement - Cohort 3: Other INI1-deficient/aberrant tumors, including: Epithelioid sarcoma (ES), Epithelioid malignant peripheral nerve sheath tumor (EMPNST), Extraskeletal myxoid chondrosarcoma (EMC), Myoepithelial carcinoma, Renal medullary carcinoma (RMC), Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 8 weeks of treatment and then every 8 weeks thereafter while on study.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02601950 STU00201778
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell …
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.
Gordon, Leo I IGordon, Leo I I
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02631044 STU00201825
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
SMART Weight Loss Management
SMART is a 12-month weight loss research study taking place in the Department of Preventive Medicine at Northwestern University. SMART includes a 3-month weight loss program at no cost. The purpose of this research is to determine the best initial strategy for weight loss…
SMART is a 12-month weight loss research study taking place in the Department of Preventive Medicine at Northwestern University. SMART includes a 3-month weight loss program at no cost. The purpose of this research is to determine the best initial strategy for weight loss and best follow-up approach for those who need more support from a weight loss program
You are between the ages of 18 - 60 years old.
You will live in the Chicagoland area for the next 12 months.
You are NOT currently pregnant, trying to become pregnant, or breastfeeding.
You do NOT have an unstable medical condition.
You own an Android or iPhone smartphone.
You are willing to track your lifestyle behaviors using a smartphone for 3 months.
Spring, BonnieSpring, Bonnie
  • Map it 680 N. Lake Shore Drive Suite 1410
    Chicago, IL
NCT02997943 STU00202075
More Info

For more information on this study please contact us:

Martindale, Laura 312 503 1395
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the …
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.
Frankfurt, OlgaFrankfurt, Olga
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02577406 STU00201848
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
An e-Health Intervention to Improve Symptom Burden and Health-Related Quality of Life among Hispanic Women Completing Active Treatment for Breast Cancer
The purpose of this study is to compare 2 health applications designed to address the wellbeing of Hispanic/Latina breast cancer patients. These hea…
The purpose of this study is to compare 2 health applications designed to address the wellbeing of Hispanic/Latina breast cancer patients. These health applications are delivered through a phone and are designed to help address wellbeing after breast cancer treatment. The applications are interactive and include videos, as well as important resources. Participation consists of completing in 1 in-person meeting, using one of the phone applications for 6 weeks on your own time, and completing 2 follow-up phone interviews. // El propósito de este estudio es comparar 2 aplicaciones de salud enfocadas en el bienestar de pacientes hispanas / latinas después del cáncer de seno. Estas aplicaciones de salud se entregan a través de un teléfono y están diseñadas para abordar el bienestar después del tratamiento del cáncer de mama. Las aplicaciones son interactivas e incluyen videos, así como recursos importantes. Participación consiste en completar 1 cita en persona, usar una aplicación de teléfono por 6 semanas, y hacer 2 entrevistas por teléfono después de usar la aplicación.
You may qualify if you: 1) Identify as Hispanic or Latina, 2) are able to read English or Spanish, 3) have been diagnosed with breast cancer and 4) have completed breast cancer treatment no more than 2 years ago (current hormonal treatment and target therapy allowed). //
Usted podría ser elegible si: 1) se identifica como Hispana/Latina 2) puede leer y escribir en inglés o en español 3) ha sido diagnosticada con cáncer de seno y 4) ha completado su tratamiento, no mas de 2 años atrás (el uso actual de terapia hormonal o terapia localizada es permitido).
Yanez, BetinaYanez, Betina
  • Map it 633 N. St. Clair St.
    Chicago , IL
STU00201961
More Info

For more information on this study please contact us:

Buitrago, Diana 312 503 2866
Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the…
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking the study drug causes any significant or undesirable side effects in women with DCIS. The researchers hope that this study will help them determine if taking the study drug is safe in women taking DCIS and if it can possibly reduce the risk of developing breast cancer in women with DCIS.
Some of the eligibility criteria include:

- Participants must be postmenopausal women with newly diagnosed DCIS scheduled to undergo surgical therapy.
- Patients must be able to swallow the oral medication.
- Patients must be able to understand and the willing to sign a written informed consent document and comply to all procedures.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kulkarni, SwatiKulkarni, Swati
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02694809 STU00202100
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Trial of CMB305 and Atezolizumab in Patients With Sarcoma
This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-E…
This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1 recombinant protein plus GLA-SE]) in combination with atezolizumab or atezolizumab alone, in patients with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. CMB305 is a novel approach designed to stimulate the body's immune system to fight the spread and growth of cancer in patients whose tumors express the NY-ESO-1 protein. LV305 will be given in a prime-boost approach with G305 to induce a potentially synergistic immunotherapeutic response in combination with atezolizumab.
Agulnik, MarkAgulnik, Mark
NCT02609984 STU00202061
More Info

For more information on this study please contact us:

1-855-NU-STUDY
(CIRB) NRG-CC003: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Purpose The purpose of the first portion of this study is to test whether whole brain radiation that minimizes dose to the hippocampus (a brain st…
Purpose The purpose of the first portion of this study is to test whether whole brain radiation that minimizes dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation is effective as the usual treatment, whole-brain radiation, in decreasing the chance of cancer spreading to the brain. The second portion of this study will test if hippocampal avoidance decreases the side effects of radiation on memory and other thought processes. Overview Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. Description of Treatment This study has two groups. A computer will by chance, like a flip of a coin assign participants to treatment groups in the study. This is called randomization. Group 1 will receive whole-brain radiation (usual care).Group 2 will receive whole-brain radiation with hippocampal avoidance. Participants and their doctor will decide if they will also receive the medicine, memantine. Memantine is not being studied in this trial. Memantine is a pill commonly given during radiation to the brain that may decrease the risk of side effects on memory and thinking.
Some of the eligibility criteria include:

- Participants must be 18 years of age or older.
- Participants must have small cell lung cancer (SCLC).

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kruser, TimothyKruser, Timothy
  • Map it 201 E. Huron St.
    Chicago, IL
STU00202336
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor …
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC), urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), and renal cell carcinoma (RCC, first line) Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head and neck squamous cell carcinoma (HNSCC).
Kircher, SheetalKircher, Sheetal
NCT01772004 STU00201857
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating …
This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride both work to stop the growth of tumor cells by blocking enzymes that are needed for cell growth. It is not yet known whether sapanisertib may be more effective than standard treatment with pazopanib hydrochloride in treating patients with locally advanced or metastatic sarcoma.
Agulnik, MarkAgulnik, Mark
NCT02601209 STU00202392
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies
Activity of COTI-2 has been demonstrated in the OVCAR-3 ovarian cancer tumor model. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment …
Activity of COTI-2 has been demonstrated in the OVCAR-3 ovarian cancer tumor model. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies. This study is designed primarily to assess the safety and tolerability of COTI-2 in patients with advanced and recurrent gynecologic malignancies and to establish a recommended Phase 2 dose (RP2D) for future studies.
Nieves-Neira, WilbertoNieves-Neira, Wilberto
NCT02433626 STU00202555
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) prolongs progression free survival (P…
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) prolongs progression free survival (PFS) and overall survival (OS) in participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification.
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02573324 STU00202233
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramos…
This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may kill tumor cells by blocking blood flow to the tumor, by stimulating white blood cells to kill the tumor cells, or by attacking specific tumor cells and stop them from growing or kill them. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Chandra, SunandanaChandra, Sunandana
NCT02339571 STU00202372
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type
The main goal of this study is to test the safety and tolera…
The main goal of this study is to test the safety and tolerability of multiple injections subcutaneously (under the skin) or an IV infusion of MRG-106, in patients with CTCL, MF subtype.
Diagnosed with CTCL, MF subtype, Stage 1,2 or 3, have at least one lesion that is a raised plaque or tumor, have not had an adequate response to other CTCL therapies, and are capable of self care.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02580552 STU00201702
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
NU 15B08: A Phase II Single Arm Study of Palbociclib in Patients with Metastatic HER2-positive Breast Cancer with Brain Metastasis
Purpose The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain. And to d…
Purpose The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain. And to determine the overall radiographic response rate in the CNS. Overview Palbociclib is an anti-cancer medication that has been shown to stop cancer cells from growing. It has been approved in hormone positive breast cancer, along with other hormone therapies and has been found to be effective. The preclinical studies suggest that the drug may also have activity in other types of breast cancer, such as triple negative and HER2 positive breast cancer. The study drug palbociclib is a small molecule and can penetrate the meninges. The purpose of this study is to see if the study drug is effective in patients with brain metastasis, who have triple negative and HER2-positive breast cancer. Description of Treatment All study participants will get the study drug in the form of a pill that will be taken once a day for 21 days followed by a 7 day break. These 28 days is considered as one cycle. The participants with HER2-positive breast cancer may also receive trastuzumab (standard of care) concurrently.
Some of the eligibility criteria include:

- Participants who have been diagnosed with triple negative or HER2-positive metastatic breast cancer.
- Participants must have been treated previously with more than two lines of chemotherapy for metastatic disease.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
STU00202582
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the …
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near the same place after a period of time during which the cancer could not be detected (locally recurrent). Glembatumumab vedotin may shrink the tumor by binding to tumor cells and delivering tumor-killing substances to them.
Chandra, SunandanaChandra, Sunandana
NCT02363283 STU00202433
More Info

For more information on this study please contact us:

1-855-NU-STUDY
High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B works compared with pembrolizumab in treatin…
This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether high-dose recombinant interferon alfa-2B is more effective than pembrolizumab in treating patients with melanoma.
Chandra, SunandanaChandra, Sunandana
NCT02506153 STU00202453
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient's immune system attack their tumor (glioblastoma multiforme - GBM). …
The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient's immune system attack their tumor (glioblastoma multiforme - GBM). These drugs have already shown benefit in some other cancer types and are now being explored in GBM. Both tremelimumab and durvalumab (MEDI4736) are "investigational" drugs, which means that the drugs are not approved by the Food and Drug Administration (FDA). Both drugs are antibodies (proteins used by the immune system to fight infections and cancers). Durvalumab attaches to a protein in tumors called PD-L1. It may prevent cancer growth by helping certain blood cells of the immune system get rid of the tumor. Tremelimumab stimulates (wakes up) the immune system to attack the tumor by inhibiting a protein molecule called CTLA-4 on immune cells. Combining the actions of these drugs may result in better treatment options for patients with glioblastoma.
Some of the eligibility criteria include:

- Patients must be age = 18 years. Both male and female are eligible.
- Patients must have a grade III or IV glioma that has failed standard RT and TMZ.
- Patients must have had radiographic evidence of tumor progression by brain MRI or CT scan.
- Patients must be surgical candidates.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Raizer, Jeffrey JRaizer, Jeffrey J
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02794883 STU00202283
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylat…
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib tosylate alone. It is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the same, or worse than sorafenib tosylate alone.
Matsangou, MariaMatsangou, Maria
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02143726 STU00202628
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer
This randomized phase II trial studies how well efatutazone with paclitaxel compared to paclitaxel alone works in treating patients with advanced anaplastic thyroid cance…
This randomized phase II trial studies how well efatutazone with paclitaxel compared to paclitaxel alone works in treating patients with advanced anaplastic thyroid cancer. Drugs used in chemotherapy, such as efatutazone and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells by stopping them from dividing or by stopping them from spreading. It is not yet known whether efatutazone in combination with paclitaxel is more effective than paclitaxel alone in treating patients with advanced anaplastic thyroid cancer.
Matsangou, MariaMatsangou, Maria
NCT02152137 STU00202641
More Info

For more information on this study please contact us:

1-855-NU-STUDY
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Ma, ShuoMa, Shuo
NCT02717611 STU00202572
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or…
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Gradishar, William JGradishar, William J
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02488967 STU00203129
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + b…
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Hussain, MahaHussain, Maha
NCT01809691 STU00202881
More Info

For more information on this study please contact us:

1-888-NU-STUDY
Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer
Este estudio está diseñado para ayudar a los hombres a mejorar la calidad de vida y reducir los síntomas del cáncer de próstata. El estudio imparte habilidades de manejo de estrés y prom…
Este estudio está diseñado para ayudar a los hombres a mejorar la calidad de vida y reducir los síntomas del cáncer de próstata. El estudio imparte habilidades de manejo de estrés y promueve la salud. Este programa de salud e intervención para hombres diagnosticados con cáncer de próstata, ofrece información sobre cómo reducir el estrés y aprender a relajarse. Este estudio dentro Northwestern University está financiado por el Instituto Nacional del Cáncer. El objetivo del estudio es examinar cómo los programas de salud pueden mejorar la calidad de vida de los hombres tratados por cáncer de próstata.
(a) ≥ 18 years of age;
(b) Hispanic/Latino self-identification;
(c) Spanish speakers (including bilinguals who express interest in a Spanish-based psychosocial intervention); (d) Willingness to be randomized and followed for approximately 12 months.
(d) Primary diagnosis of localized Prostate Cancer (T1-T3, N0, M0);
(e) Surgical or radiation treatment (e.g., external beam, brachytherapy, proton) within the past 24 months prior to participating in the study
Penedo, Frank JPenedo, Frank J
  • Map it 633 N. St. Clair St.
    Chicago , IL
NCT03344757 STU00203197
More Info

For more information on this study please contact us:

Pizarro, Edgar 312 503 3949
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to investigate the safety, tolerability, and antitumor activity of MEDI4736 (durvalumab, ant…
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to investigate the safety, tolerability, and antitumor activity of MEDI4736 (durvalumab, anti-PD-L1) in combination with tremelimumab (anti-CTLA-4), MEDI4736 monotherapy, or tremelimumab monotherapy in the treatment of metastatic or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma. MEDI4736 and tremelimumab are both investigational drugs, which means they are not approved by the FDA.
Participants must be 18 years of age or older. Participants who have gastric (stomach) cancer or cancer of the gastroesophageal junction (GEJ) (where the esophagus meets the stomach) that has returned after treatment (is recurrent), or has spread to another area of the body (is metastatic).
Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02340975 STU00202602
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.…
The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.
Kumthekar, PriyaKumthekar, Priya
NCT02511405 STU00202202
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival tha…
The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.
Gradishar, William JGradishar, William J
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02492711 STU00202637
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Comparing FDA approved MRI contrast agent with a new agent. The new agent is thought to better detect brain and spinal cord lesions (mass or tumors) and may help in better treatment.Patients with any brain or s…
Comparing FDA approved MRI contrast agent with a new agent. The new agent is thought to better detect brain and spinal cord lesions (mass or tumors) and may help in better treatment.Patients with any brain or spinal cord mass may be eligible to join the study. All study related procedural expenses will be covered by the study.
Inclusion criteria:

1. Female or male adult subject (subject having reached legal majority age).
2. Subject presenting, at the time of inclusion, with known or highly suspected focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors, focal inflammatory or demyelinating disorders) including at least one expected enhancing lesion of minimum 5 mm (long axis). This lesion must have been detected on a previous imaging procedure (computerized Tomography (CT) or MRI).
3. Subject scheduled for a routine CNS contrast-enhanced MRI examination for clinical reasons and agreeing to have a second contrast-enhanced MRI examination for the purpose of the study.
4. Subject able and willing to participate to the study
Non-inclusion criteria:
1. Subject presenting with acute or chronic Grade III (at least) renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73m² based on two eGFR assessments, one within 7 days before the first study MRI and one the day of the MRI (if any of the eGFR result is <60 mL/min/1.73m², the subject is not eligible).
2. Subject presenting with known class III/IV congestive heart failure according to the New York Heart Association classification (NYHA).
3. Pregnant or breast-feeding female subject (a female subject of childbearing potential or with amenorrhea for less than 12 months must have a negative urine or serum pregnancy test within 24 hours prior to study MRI and must be using a medically approved contraception method* until the last study visit).
4. Subject having received any investigational medicinal product within 30 days prior to study entry.
5. Subject previously enrolled in this study.
6. Subject presenting with any contraindication to MRI examinations.
7. Subject with known contra-indication(s) to the use or with known sensitivity to one of the products under investigation or other GBCAs.
8. Subject having received any contrast agent (MRI or CT) within 3 days prior to study products administration, or scheduled to receive any contrast agent during the course of the study and within 24 hours after the second study product administration.
9. Subject having received any treatment or medical procedure (e.g. chemotherapy, radiotherapy, biopsy or surgery etc…) within 7 days prior to the first MRI or expected/scheduled to have a change in any treatment or medical procedure (e.g. chemotherapy, radiotherapy, biopsy or surgery etc…) in-between the 2 MRI examinations.
10. Subject with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the subject’s safety or her/his ability to participate in the study.
11. Subject unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for follow-up visits and/or unlikelihood of completing the study).
12. Subject related to the Investigator or any other study staff or relative directly involved in the study conduct.

Liu, BenjaminLiu, Benjamin
NCT02633501 STU00202835
More Info

For more information on this study please contact us:

Muzaffar, Ayesha 312 926 4251
A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas
This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back a…
This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Kumthekar, PriyaKumthekar, Priya
NCT02523014 STU00202953
More Info

For more information on this study please contact us:

1-855-NU-STUDY
NU 16I01: Phase I/Ib study of nivolumab in combination with Therasphere (yttrium-90) in patients with advanced hepatocellular carcinoma.
Purpose The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unaccept…
Purpose The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unacceptable side effects, for combination treatment of nivolumab and Y-90. Also, to evaluate the efficacy (the effect of drug on your tumor) and the tolerability (the effect of the drug on your body) of nivolumab, when given with standard of care Y-90 (Therasphere). Overview Nivolumab is currently FDA approved for other cancers, but has not yet been investigated in advanced or refractory hepatocellular carcinoma. Nivolumab is an antibody (a human protein that sticks to a part of the tumor and/or immune cells) designed to allow the body‰Ûªs immune system to work against tumor cells. Y-90 is currently FDA approved for the treatment of hepatocellular carcinomas, but has not yet been investigated in combination with nivolumab for this disease. This is a phase I study of 2 drugs used in combination: nivolumab and Y-90. We think the combination of these drugs may be more effective against your cancer. Description of Treatment All study participants will get the same study intervention. All study participants will get the study drug Nivolumab. You will receive induction treatment with Y-90, and then approximately four weeks after, you will receive Nivolumab once every 2 weeks (given through the vein over 30 minutes). After you finish your treatment with nivolumab, the study team will continue to watch you for side effects for up to 30 days from your last treatment. If you discontinue from the study for any reason, the study team will continue to check how you are doing every 2 weeks for up to 24 weeks from the start of your treatment.
Some of the eligibility criteria include:

- Patients must have a diagnosis of hepatocellular carcinoma.
- Patients must have advanced disease that is not amenable to transplant or resection.
- Patients may be treatment naÌøve or have received any number of prior therapies

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kalyan, AparnaKalyan, Aparna
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02837029 STU00203003
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NU 15U06: A Phase 1 Dose-Escalation Study of Intravesical Pembrolizumab and Bacillus Calmette-Guerin (BCG) in Subjects with High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
Purpose The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerabili…
Purpose The purpose of this study is to evaluate the efficacy (the effect of drug on tumor) and the tolerability (the effect of drug on the body) of Pembrolizumab, when given as a single agent in patients with bladder tumors. Another purpose of the study is to see what tumor characteristics are associated with increased efficacy of the Pembrolizumab. Overview Pembrolizumab (MK-3475) is an antibody (a human protein that sticks to a part of the tumor and/or immune cells) designed to allow the body‰Ûªs immune system to work against tumor cells. Pembrolizumab is FDA approved for the treatment of advanced melanoma (a type of skin cancer) and some types of lung cancer. It is not yet approved by the USFDA for bladder cancer, hence it is considered an investigational agent for this disease. Description of Treatment All study participants will take the same study drug, Pembrolizumab. Pembrolizumab will be given intravesically through urethra. With intravesical therapy, doctor administers the drug directly into the bladder (through a catheter), rather than giving it by mouth or injecting it into a vein. During the first six weeks of therapy, one will also receive treatment with BCG as a standard of care. We expect that one will receive treatment for up to 1 year or until your disease gets worse (whichever occurs first). After completing treatment, the study team will continue to watch you for side effects for at least 30 days. The study team will also continue to check periodically to see how you are doing until your disease returns.
Some of the eligibility criteria include:

- Participants must have a recurrent, high or low risk non-muscle-invasive bladder carcinoma.
- Participants must (be BCG refractory) have received at least one 6-week course of BCG induction plus 1 maintenance dose, OR 2 full 6-week courses of induction BCG treatment.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Meeks, Joshua JMeeks, Joshua J
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02808143 STU00202754
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this research study is to determine the acceptable upper limit dose of nivolumab in combination with dasatinib that may be given t…
The purpose of this research study is to determine the acceptable upper limit dose of nivolumab in combination with dasatinib that may be given to patients with relapsed/refractory philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Nivolumab is currently Food and Drug Administration (FDA) approved for other cancers, but has not yet been investigated in Ph+ ALL. Dasatinib is currently FDA approved for the treatment of Ph+ ALL, but has not yet been investigated in combination with nivolumab for this disease. There is evidence that dasatinib not only blocks the Philadelphia chromosome or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) mutation, but also increases the activity of cells in your immune system. Nivolumab increases T cells in your immune system, which allows your immune system to attack the cancer. We think the combination of these drugs will be more effective against your leukemia than either drug used alone.
Some of the eligibility criteria include:

- Patients must have a histologically confirmed diagnosis of Ph+ ALL.
- Patients must have primary refractory ALL based on failure to achieve a hematologic or molecular remission after induction therapy with dasatinib and steroids or dasatanib and chemotherapy, or have relapsed after treatment with a tyrosine kinase inhibitor with or without chemotherapy.
- Patients must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Dinner, ShiraDinner, Shira
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02819804 STU00202846
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NRG GY004-A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Purpose The purpose of this study is to evaluate the eff…
Purpose The purpose of this study is to evaluate the efficacy either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer. Overview This study will allow the researchers to learn whether giving olaparib by itself or giving the combination of cediranib and olaparib is better, the same, or worse than the usual chemotherapy by observing both the effect of these treatments as well as any side effects that may be experienced. Description of Treatment This study has three study groups: ‰Û¢ Group 1 will get standard chemotherapy with one of three regimens: Regimen I: Carboplatin in your vein (IV) on day 1, and Paclitaxel IV over 3 hours on day 1, every 21 days Regimen II: Carboplatin IV on day 1, and Gemcitabine IV on days 1 and 8, every 21 days Regimen III: Carboplatin IV on day 1, and PLD IV on day 1, every 28 days Group II: Olaparib alone; taken as a tablet twice per day continuously Group III: Olaparib and cediranib: Olaparib taken as a tablet twice per day and cediranib taken as a tablet once per day on a continuous basis.
Some of the eligibility criteria include:

- Some of the eligibility criteria include:
- Participants must be 18 years of age or older.

- Patients must have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers.

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Shahabi, ShohrehShahabi, Shohreh
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02446600 STU00203121
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
Purpose The purpose of this research study is to determine the effects (good and bad) bevacizumab (the study drug) combined with Optune (the stud…
Purpose The purpose of this research study is to determine the effects (good and bad) bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Overview Bevacizumab (the study drug) is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. In order for tumors to grow they need to have a blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune (the study device) is also considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study device, Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient‰Ûªs brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed. Description of Treatment Tumor treatment field therapy with Optune will be initiated at the same time as bevacizumab, with both treatments to start within a one-week period of each other. Bevacizumab will be given at current standard central nervous system (CNS) dosing of 10mg/kg q2 weeks in an outpatient setting. After 4 cycles (1 cycle=28days) of therapy (Cycle 5 day 1) patients may choose to switch to bevacizumab at a dose of 15 mg/kg q3 weeks. For patients who chose to make this switch, they have to do it on Day1 of a new cycle. Tumor treatment fields with Optune will be delivered for at least 18 hours a day at a frequency of 200 KHz and intensity of 1-3V/cm. Treatment will be continued until disease progression or up to 1 year.
"Some of the eligibility criteria include:

- Patients must be age = 18 years. Both males and females and patients from all

ethnic backgrounds are eligible.
- Patients must have a histologic diagnosis of meningioma, WHO grade 2 or 3 (atypical or anaplastic).
- All patients must have developed recurrent disease/progression after receiving all standard treatments.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial."
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
STU00203030
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) Form of Cutaneous T-Cell Lymphoma (CTCL)
The main goal of this study is to test the …
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
AHA Strategically Focused Research Network: mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health-Study 2
NUYou is a two year cardiovascular health study using a mobile app.
The study is closed to recruiting. To test whether a health intervention in the form of a mobile phone
application will preserve or improve heart healthy behaviors (nonsmoking, healthy diet, physical
activity, healthy weight) and cardiovascular health biomarkers (blood pressure, and fasting
cholesterol and glucose) in college students between their freshman and junior year.
Spring, BonnieSpring, Bonnie
STU00202845
More Info

For more information on this study please contact us:

Hood, Susan 312 503 0945
DRUG CC-90009-AML-001: A Phase 1, Open-Label, Dose-Finding Study Of Cc-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia
Purpose CC-90009 is a new investigational product (IP) that has a strong biological rationale for the treatment o…
Purpose CC-90009 is a new investigational product (IP) that has a strong biological rationale for the treatment of subjects with AML. This Phase I study is designed to determine the safety and tolerability of CC-90009 as well as evaluating the biologic and clinical activity in subjects with relapsed or refractory AML. Overview CC-90009 binds to a protein in your body called cereblon and affects how cereblon functions. Laboratory and animal studies showed that CC-90009 can slow down the growth or kill cancer cells in AML by preventing cereblon from working. Description of Treatment The study has 2 parts, dose escalation (Part A) and dose expansion (Part B). Based on when you agree to participate in the study, you may be selected to participate in either part, but not both parts. You will be treated with CC-90009 administered intravenously (directly into a vein) on Days 1-5 of each cycle for up to 4 cycles. Additional schedules for dosing may be tested (such as more or less consecutive days). Your study doctor will tell you which schedule you will take and you will be provided a revised ICF to review and sign. The number of cycles will be determined by your study doctor based on whether you are receiving benefit from the treatment. Each cycle is 28 days with the possible exception of Cycle 1. Depending on how well you do on the study treatment(s), you may receive the study treatment(s) for a maximum of 4 months. If you are improving following the treatment or your cancer has disappeared, you will continue to be monitored by your study doctor in the study until you have a relapse (your cancer comes back). You may be in the study for as little as a few days or until approximately 2 years after your last dose (due to follow-up).
Some of the eligibility criteria include:

- Men and women 18 years of age or older, at the time of signing the ICD
- Relapsed or primary refractory AML that is recurrent or refractory, or the subject is intolerant to established therapy.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Altman, Jessica KAltman, Jessica K
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02848001 STU00203119
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
Purpose The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it take…
Purpose The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take the study drugs. Overview All participants will be treated with guadecitabine and pembrolizumab. Guadecitabine is a drug that acts on the cancer cells‰Ûª DNA. DNA is present inside all cells and guides how proteins are made. Guadecitabine interferes with the cancer cells‰Ûª DNA and can increase the production of certain proteins, making cancer cells more recognizable by the immune system. Pembrolizumab helps your immune system to kill cancer cells. Thus the combination of guadecitabine and pembrolizumab may increase the ability of the immune system to eliminate cancer cells. Researchers want to find out whether the combination of guadecitabine and pembrolizumab is effective in treating ovarian cancer that has not responded to traditional chemotherapy. Participants will keep receiving treatment until their cancer gets worse, they have side effects, or they decide they don't want to receive the treatment anymore. After stopping treatment, the study doctor will watch participants for side effects and follow their condition every 6-12 weeks. We would like to keep track of participants' medical conditions for the rest of their lives. This helps us look at the long-term effects of the study drugs. Description of Treatment All subjects will be treated in cycles lasting 21 days (3 weeks). Participants will receive guadecitabine as an injection on Days 1-4 (Monday-Thursday) of each cycle, then will receive pembrolizumab through a vein on Day 5 (Friday) of each cycle. Participants will keep receiving treatment until their cancer gets worse, they have side effects, or they decide they don't want to receive the treatment anymore.
Some of the eligibility criteria include:

- participants must have ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube cancer.
- participants must have receives prior treatment for their cancer.
- participants must be 18 years of age or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Matei, DanielaMatei, Daniela
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02901899 STU00203494
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this study is to test the effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). The researchers wil…
The purpose of this study is to test the effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). The researchers will study the effects of REGN2810 and how long the effects last. The information will help researchers understand if REGN2810 could be used for the treatment of advanced CSCC. REGN2810 is an investigational drug. “Investigational” means that it is not approved by the US Food and Drug Administration (FDA).
Patients with unresectable locally advanced cutaneous squamous cell carcinoma (CSCC). Patients are required to have disease that is considered inoperable or to have medical contraindication to surgery or radiation, or have not achieved disease control with these treatments.
Alam, MuradAlam, Murad
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02760498 STU00202715
More Info

For more information on this study please contact us:

Wu, Benedict 312 503 5907
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Purpose This is a Phase III study to assess the effect of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS) Overview This study will allow the researchers to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Description of Treatment This study has two study groups. Group 1 will receive a placebo in the form of a tablet that looks like the study drug but contains no medication, and Group 2 will receive the study drug olaparib in the form of a tablet. A computer will by chance assign patients to treatment groups in the study. This is called randomization. This is done by chance because no one knows if one study group is better or worse than the other.
Some of the eligibility criteria include:

- Female or Male participants must be 18 years of age or older.

a) For patients who underwent initial surgery and received adjuvant chemotherapy

-TNBC patients must have been axillary node-positive (>/= pN1, any tumor

size) or axillary node negative (pN0) with invasive primary tumor

pathological size > 2 cm (>/= pT2).

-ER and/or PgR positive/HER 2 negative patients must have had >/= 4 pathologically confirmed positive lymph nodes.

b) For patients who underwent neoadjuvant chemotherapy followed by surgery

-TNBC patients must have residual invasive breast cancer in the breast and/or

resected lymph nodes (non-pCR)

-ER and/or PgR positive/HER2 negative patients must have residual invasive

cancer in the breast and/or the resected lymph nodes (non-pCR) AND a CPS&EG score >/= 3.

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02032823 STU00203491
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
ECOG-ACRIN 2133: An International Multicentre Open Label Randomized Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil (5-FU) versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease
Purpose The purpose of this study is …
Purpose The purpose of this study is to establish the standard of care for advanced or metastatic anal cancer. Due to the fact that anal cancer is a relatively rare disease, there is currently no nationally and internationally agreed standard chemotherapy treatment. At present, the most frequently prescribed chemotherapy is a combination of two drugs called cisplatin and 5-fluorouracil. However, a formal comparison of this combination with other chemotherapies (potentially more effective, or equally effective but potentially less toxic) has never been performed. Overview Carboplatin and paclitaxel is the standard chemotherapy regime for patients with ovarian cancer and is also effective in other diseases, such as lung cancer. Participants with a diagnosis of anal cancer that cannot be treated with surgery may participate in this study that will compare the combination of cisplatin and 5-fluorouracil with the combination of carboplatin and paclitaxel. Description of Treatment Group 1 will receive a combination of two drugs called cisplatin and 5-fluorouracil. Group 2 will receive a combination of two drugs called carboplatin and paclitaxel.
Some of the eligibility criteria include:

- Participants must be 18 years of age or older.
- Participants must have anal cancer that has returned following initial treatment or has spread to other areas of the body.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02560298 STU00203731
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase II, Open label Study to evaluate Denosumab in patients with ER and/or PR-positive, HER2-negative Metastatic Breast Cancer (MBC) with bone metastases and detectable circulating tumor cells (CTCs)
Purpose The purpose of this study is to look at the amount of cancer cells in the blood of part…
Purpose The purpose of this study is to look at the amount of cancer cells in the blood of participants who are being treated with denosumab. The other purpose is to look at how long it takes for cancer to get worse when participants are being treated with denosumab. Overview Circulating tumor cells (CTCs) in the blood of patients with metastatic breast cancer (MBC) have been associated with shorter survival than when CTCs are absent, especially in patients whose cancer has spread to their bones. In this study, we want it see if denosumab (the study drug) will decrease the number of CTCs measured in patients with MBC and cancer that has spread to their bones. We plan to give 3 doses of denosumab (one every 4 weeks) and find out if it has any effect on CTCs as well as the time it takes for cancer to get worse. We also plan to get blood from participants to study other research markers of interest. Description of Treatment Participants will be asked to come to the outpatient clinic on Day 1 of study treatment. Participants will have a physical exam and blood draw for routine tests then receive the first dose of the study drug (denosumab) which is given subcutaneously (injected under the skin). Participants will continue on the standard of care treatment plan that their doctor recommends (hormones or chemotherapy). Participants will continue to receive injections of denosumab approximately every 28 days (28 days equals 1 cycle). We will check the status of each participant's cancer after every 12 weeks of therapy with imaging tests. Participants will continue to receive study treatments for 3 cycles (12 weeks) or until a) their cancer gets worse, b) they experience serious side effects, or c) they and/or their doctor feel it is best to stop study treatment. After discontinuing treatment for any reason, participants will be followed by the study team approximately every 12 weeks to see how they are doing. Participants will be followed until their cancer gets worse again, they begin another type of treatment for cancer, or they complete 2 years of follow-up.
Some of the eligibility criteria include:

- participants must have breast cancer that has spread to the bones.
- participants must have breast cancer that is Her2 negative and ER and/ or PR positive.
- participants must be 18 years of age or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
STU00203216
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma
Purpose The purpose of this study is to compare the effects, good and bad, of chemotherapy given before surgery to remove the affected upp…
Purpose The purpose of this study is to compare the effects, good and bad, of chemotherapy given before surgery to remove the affected upper urinary tract for people with upper tract urothelial cancer. Overview The usual treatment for upper tract urothelial cancer is surgery to remove the affected upper urinary tract. However, this often results in loss of kidney function, which may prevent doctors from safely giving chemotherapy after surgery. In this study, doctors are looking to see if there are any good and bad effects of chemotherapy given before surgery, at the time when kidney function is at its maximum. Methotrexate, vinblastine, doxorubicin, cisplatin and pegfilgastrim (AMVAC) and gemcitabine and carboplatin (GC) are FDA-approved medicines used to treat urothelial and other cancers. Researchers hope to learn what percentage of patients will have their cancer eliminated completely by chemotherapy before surgery. Description of Treatment Study participants will be assigned to one of the two study groups (Group 1 or Group 2) based on their kidney function. Both groups will receive chemotherapy followed by surgery. Participants with normal or near normal kidney function will be assigned to Group 1. Group 1 will be given methotrexate, vinblastine, doxorubicin, cisplatin and pegfilgastrim (AMVAC) on the first day of every cycle for 4 total cycles. Each cycle is 14 days long. Participants will have surgery to remove their tumor 21 to 60 days after finishing the chemotherapy. Participants with decreased kidney function will be assigned to Group 2. Group 2 will be given gemcitabine and carboplatin (GC) for four cycles. Each cycle is 21 days long. Gemcitabine will be given on day 1 and day 8 of each cycle. Carboplatin will be given on day 1 of each cycle. Participants will have surgery to remove their tumor 21 to 60 days after finishing the chemotherapy.
Some of the eligibility criteria include:

- Participants must have high grade upper tract urothelial carcinoma
- Participants must be at least 18 years of age

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Meeks, Joshua JMeeks, Joshua J
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02412670 STU00204184
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
DRUG WO29636: A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma after Surgical Resection
Purpose The purpose of this clinical research study is to test …
Purpose The purpose of this clinical research study is to test the safety and tolerability of the research study drug, atezolizumab, versus observation (not receiving any treatment) on participants with cancer of urinary tract (including, renal pelvis or ureters) that has spread to the muscle layer (muscle-invasive urothelial carcinoma). Overview This study is set up to look at the tolerability and the safety of the use of atezolizumab versus observation on urothelial cancer. Atezolizumab is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the programmed death-ligand 1 (PD L1) pathway. By blocking the PD L1 pathway, atezolizumab may help the immune system to stop or reverse the growth of tumors. Description of Treatment Participants will be randomly (based on chance, like a flip of a coin) assigned to the study drug or observation only arm. Participants assigned to the atezolizumab group may continue to receive atezolizumab for up to 1 year as long as they are tolerating atezolizumab and the cancer does not come back. Atezolizumab will be given through a vein over a period of about 60 minutes every 3 weeks. Participants assigned to the observation group will not receive any treatment but will be monitored for up to 1 year as long as the cancer does not come back.
Some of the eligibility criteria include:

- Participants must have bladder cancer
- Participants must be 18 or older
- Participants must not have any approved anti-cancer therapy within 3 weeks prior to taking part in this study

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Hussain, MahaHussain, Maha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02450331 STU00204003
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
OT-15-001: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Purpose The purpose of this study i…
Purpose The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Overview Elfornithine is an experimental drug. An experimental drug means that the United States Food and Drug Administration (FDA) has not approved it for use. This drug will be used with another drug called Lomustine that is approved by the FDA in the United States for patients with anaplastic astrocytoma. Description of Treatment This study has two study groups. Patients will be randomly placed in one of the 2 groups.
Some of the eligibility criteria include:

- Participants must be 18 years of age or older.

- Patients must have surgical or biopsy proven diagnosis of WHO grade 3 Anaplastic Astrocytoma

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02796261 STU00203957
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NU 16U05: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Purpose The purpose of this research is to study two US FDA approved drugs alone or in combination with each other in p…
Purpose The purpose of this research is to study two US FDA approved drugs alone or in combination with each other in people who have metastatic castration-resistant prostate cancer and specific changes in their DNA, to see which one is best at keeping prostate cancer from growing. Metastatic castration-resistant prostate cancer means the cancer is spreading outside of the prostate and does not stop or go away with hormone therapy or surgery to reduce testosterone. One of the drugs, Olaparib, is not FDA approved for prostate cancer, which means it is experimental or investigational. Overview Once prostate cancer has progressed to metastatic castration-resistant prostate cancer, standard treatment focuses on extending life, delaying disease progression, and improving symptoms and quality of life. The purpose of this research is to study two US FDA approved drugs alone and in combination with each other in people who have metastatic castration-resistant prostate cancer and DNA repair defects. One of the drugs, Olaparib, is not FDA approved for prostate cancer. People who take part in this research study have been diagnosed with metastatic castration-resistant prostate cancer and either their body or the the cancer have a genetic defect (flaw) that causes problems with their body‰Ûªs ability to repair damage to their DNA. Description of Treatment Participants will be placed into one of four groups. The treatment that each group will receive is as follows. Group 1 will receive Abiraterone (1000 mg by mouth once per day) and prednisone (5 mg by mouth twice per day). Group 2 and 4 will receive Olaparib (300 mg by mouth twice per day). Group 3 will receive Olaparib (300 mg by mouth twice per day), Abiraterone (1000 mg by mouth once per day) and prednisone (5 mg by mouth twice per day). Treatment may continue until disease progression, severe or unacceptable side effects, or until the participant or study doctor think the treatment should stop.
Some of the eligibility criteria include:

- participants must have been diagnosed with prostate cancer that is metastatic (has spread outside of the prostate region) and castration-resistant (means the cancer is still growing even when testosterone levels are close to zero)
- participants must be males 18 years of age or above

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Hussain, MahaHussain, Maha
  • Map it 201 E. Huron St.
    Chicago, IL
STU00203960
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NU 16C01: A Phase 0 first-in-human study using NU-0129: a spherical nucleic acid (SNA) gold nanoparticle targeting BCL2L12 in recurrent glioblastoma multiforme or gliosarcoma patients
Purpose The purpose of this research study is to evaluate the safety of NU-0129 SNA gold nanoparticle infusion in …
Purpose The purpose of this research study is to evaluate the safety of NU-0129 SNA gold nanoparticle infusion in patients with recurrent glioblastoma multiforme or gliosarcoma Overview This is a first-in-human trial to determine the safety of NU-0129. The study drug is composed of a small gold nanoparticle that has spherical nucleic acid attached to it. This small particle allows NU-0129 to cross the blood brain barrier (a filtering mechanism that carry blood to the brain). Once within the tumor, the nucleic acid component is able to target a gene called Bcl2L12 that is present in glioblastoma multiforme, and is associated with tumor growth. This gene prevents tumor cells from apoptosis, which is the process of programmed cell death, thus promoting tumor growth. Researchers think that targeting the Bcl2L12 gene with NU-0129 will help stop cancer cells from growing. Description of Treatment All study participants will receive the same study drug, NU-0129, given through vein one time over 20 minutes as an inpatient. Within two days of getting this drug, participants will have a tumor resection surgery, recommended by their doctor. The study team will continue to watch for any side effects for at least 4 weeks with clinic visits and lab tests done each week. The study team will also continue to check how the subjects are doing with a clinic visit at least every 3 months for up to 2 years or until their disease comes back.
Some of the eligibility criteria include:

- Patients should have a diagnosis of recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS) after failing prior therapy.
- Eligible patients must be surgical candidates where surgery is felt to be an appropriate treatment option.
- Patients must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03020017 STU00203790
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NU 16H07: Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regim…
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regimen is called “ICE” and includes three drugs: ifosfamide, carboplatin, and etoposide. Pembrolizumab is currently FDA approved for the treatment of melanoma, but has not yet been investigated in Relapsed/Refractory Hodgkin Lymphoma. The ‘ICE’ regimen of chemotherapy is currently FDA approved for the treatment of Relapsed/Refractory Hodgkin Lymphoma, but has not yet been investigated in combination with pembrolizumab for this disease. This is a phase II study of these drugs used in combination. For patients who have a relapse of their Hodgkin’s lymphoma, retreatment with chemotherapy followed by a stem cell transplant is recommended. We know that obtaining a complete remission (not able to detect any disease on scans) is very important prior to proceeding to the stem cell transplant. Patients with negative scans have a lower chance of the disease coming back and a higher chance of achieving a long-term cure. Research continues to find for the best regimen to obtain a complete remission in this setting.
Some of the eligibility criteria include:
• Patients must have a histologically confirmed diagnosis of classical Hodgkin lymphoma.
• Patients must have relapsed/refractory disease, with at least one line of prior chemotherapy, but not more than 2 prior lines of treatment, for Hodgkin lymphoma.
• Patients must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Winter, Jane NormaWinter, Jane Norma
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03077828 STU00203658
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas.
Purpose The purpose of this study is to compare the effects (good and bad) of the study drugs temozolomide and cap…
Purpose The purpose of this study is to compare the effects (good and bad) of the study drugs temozolomide and capecitabine to cisplatin and etoposide, the drugs used for usual chemotherapy treatment for advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. Overview Cisplatin and etoposide is usually the first treatment given for neuroendocrine cancer. The chemotherapy drugs temozolomide and capecitabine may be used are also used to treat this disease but usually not until the first treatment, cisplatin and etoposide, stops working. It is not known if this is the best approach or if the temozolomide and capecitabine should be given first instead. Researchers are trying to determine if one chemotherapy combination is better than another for neuroendocrine cancers. Description of Treatment Study participants will be randomly assigned by chance (like the flip of a coin) to one of the two study groups. Group 1 will receive the study drugs temozolomide and capecitabine. Group 2 will receive the usual approach for this cancer; cisplatin and etoposide. Study visits will be grouped into cycles. The number of cycles of study treatment depends on how well each participant is tolerating treatment and how well the cancer responds to it. Group 1 will take the study drug capecitabine by mouth twice a day for 14 days in a row. During the last five days of the 14 days of taking capecitabine, participants will take temozolomide by mouth once a day as well. After the 14 days of treatment participants will have 14 days off from treatment before any further treatment is started. This 28-day period is one cycle for Group 1. Group 2 will receive cisplatin and etoposide through a vein. This treatment will be given at a clinic visit once a day for three days in a row, and then participants will have 18 days off before any further treatment is received. This 21-day period is one cycle for Group 2.
Some of the eligibility criteria include:

- Participants must have a locally advanced and unresectable or metastatic gastroenteropancreatic G3 neuroendocrine carcinoma of the GI tract.
- Participants must have pathologically/histologically confirmed tumor of non-small cell histology.
- Participants must be at least 18 years of age

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02595424 STU00204209
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. T…
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This rash has been shown to be inflammatory in origin but is currently treated with antibiotics if it appears. The main goal of this study is to test if patients treated with steroid cream, (added) which is an anti-inflammatory medication, (added) before a rash develops have a less severe rash than patients who do not use a steroid cream before a rash develops.
Must be 18 years of age or older with a diagnosis of cancer and starting an (changed from 'and') EGFR inhibitor. During the study you must be willing to fill out a daily diary, use sunscreen and cream daily, and fill out 2 questionnaires and have photographs taken every 2 weeks for 4 visits.
Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03115567 STU00203631
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
NU 16L04: Parallel proof of concept phase 2 study of nivolumab and metformin combination treatment in advanced non-small cell lung cancer with and without prior treatment with PD-1/PD-L1 inhibitors
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non…
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy. We will also be looking at the safety of the combination. Nivolumab is currently approved in certain cancers such as melanoma, lung cancer and kidney cancer. Metformin is approved by the US Food and Drug Administration (FDA) to treat diabetes. In this study, Metformin is being used to treat cancer. This use is not approved by the FDA; therefore, in this study, it is considered experimental. Experimental means the U.S. FDA has not approved the drug for use in your type of cancer. All study participants will get the same study intervention. All study participants will get the study drugs Nivolumab and Metformin.
Participants ages 18 or older. Participants who have an advanced non-small cell lung cancer.
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03048500 STU00204354
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis
Congenital ichthyosis is a large and varied family of inherited skin disorders characterized by dry, scaling skin that may be thickened or very thin. Thi…
Congenital ichthyosis is a large and varied family of inherited skin disorders characterized by dry, scaling skin that may be thickened or very thin. This clinical trial seeks to investigate the safety and tolerability of a topically applied ointment (PAT-001) as a treatment for congenital ichthyosis
Subjects must be at least twelve years old with clinically confirmed diagnosis of either lamellar ichthyosis or X-linked ichthyosis
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT02864082 STU00204653
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
Phase II study of nivolumab and ipilimumab for treatment of advanced adenoid cystic carcinoma and non-adenoid cystic carcinoma
Purpose The purpose of this study is to look at the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combinati…
Purpose The purpose of this study is to look at the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer. Another purpose of the study is to see which tumor markers (proteins in the blood that the body produces in response to the cancer) lead to better results in participants treated with the study drugs. Overview Nivolumab and ipilimumab are antibodies, which are human proteins that recognize and attach to a part of the tumor and/or body‰Ûªs immune cells. They work in slightly different ways to activate the immune system and help the body‰Ûªs immune system to work against tumor cells. The combination of these drugs is already approved by the FDA to treat advanced melanoma (a type of skin cancer). Nivolumab and ipilimumab are investigational because they are not approved by the FDA to be used for the type of cancer being studied. Description of Treatment All study participants will receive the same study drugs, nivolumab/ipilimumab combination, over periods called cycles (1 cycle = 12 weeks / 84 days). Nivolumab will be given through a vein over 30 minutes once every 2 weeks for the first 16 weeks. It will then be given over 60 minutes once every 4 weeks for as long as participants are benefitting. Ipilimumab will be given through a vein over 90 minutes every 6 weeks (twice each cycle). Participants will take part in the study as long as they are benefitting from the study drugs.
Some of the eligibility criteria include:

- Participants must be > 18 years old.
- Participants must have histologically or cytologically confirmed metastatic/recurrent adenoid cystic carcinoma (ACC) or non-adenoid cystic carcinomas (non-ACC) of major or minor salivary glands

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Matsangou, MariaMatsangou, Maria
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03146650 STU00204579
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase II study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
The purpose of this study is to look at the safety and efficacy of Plitidepsin in participants with relapsed or refractory angiommunoblastic T-cell lymphoma. The main goal of this research study…
The purpose of this study is to look at the safety and efficacy of Plitidepsin in participants with relapsed or refractory angiommunoblastic T-cell lymphoma. The main goal of this research study is to study the effects of plitidepsin (in combination) on participants that have angiommunoblastic T-cell lymphoma (AITL) that did not respond, or progressed after previous treatment. Plitidepsin is a new anticancer drug that has had some effect in earlier studies when used as a single agent. Plitidepsin is a drug that has not yet been approved by the FDA.
Some of the eligibility criteria include:
• Patients must have a histologically confirmed diagnosis of R/R AITL
• Life expectancy greater than 3 months
• Patients must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Pro, BarbaraPro, Barbara
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03070964 STU00204257
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Pur…
Purpose The purpose of the study is to see if a medicine called ASP2215 given alone or in combination with azacitidine is both effective and safe as a treatment for AML patients with mutations in the FLT3 gene when compared to being treated with azacitidine alone. Overview ASP2215 is a drug that is designed to slow down the growth of leukemic cells by blocking FLT3 protein on those cells. ASP2215 is an experimental drug that is being studied to treat AML. It is being tested in clinical trials and has not been approved by U.S. Food and Drug Administration (FDA) and/or any other regulatory authorities for any indication. Description of Treatment Participants will be randomly (like flipping a coin) assigned to one of three treatment groups: * Group A: ASP2215 given alone; * Group AC: ASP2215 given in combination with azacitidine chemotherapy; * Group C: azacitidine chemotherapy given alone. During the treatment period, the study is divided into periods of time called cycles. Each cycle lasts 28 days. Participants will come into the clinic each cycle for visits to get more study drug and to evaluate AML and other related health assessments.
Some of the eligibility criteria include:

- Participant is at least 18 years old.
- Subject has a diagnosis of previously-untreated AML.
- Subject is positive for FLT3 mutation (ITD or TKD [D835/I836] mutation) in bone marrow or whole blood.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Dinner, ShiraDinner, Shira
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02752035 STU00203834
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
METIS: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
The purpose of this study is to obtain information on the safety and effectiveness of NovoTTF-100M (the study device) in part…
The purpose of this study is to obtain information on the safety and effectiveness of NovoTTF-100M (the study device) in participants with brain metastases (tumors) as a result of non-small cell lung cancer (NSCLC). This study will test the efficacy, safety and neurocognitive outcomes of advanced NSCLC participants, following stereotactic radiosurgery (SRS) for brain metastases, treated with NovoTTF-100M and supportive treatment when compared to being treated with supportive treatment alone. This is a research study to test a study device, NovoTTF-100M, which is an investigational device and has not been approved by the FDA to treat this type of cancer and therefore is being considered investigational. This study has two study groups. Participants will be randomly placed into one of the two following groups; Supportive care only group OR NovoTTF-100M group.
Participants must be 18 years of age or older. Participants who have non-small cell lung cancer that has spread to the brain (brain metastases).
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02831959 STU00204448
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NCI 2015-06-04 Phase IIB trial of neoadjuvant oral tamoxifen versus transdermal 4-hydroxytamoxifen in women with DCIS of the breast
Phase IIB trial of neoadjuvant oral tamoxifen versus transdermal 4-hydroxytamoxifen in women with DCIS of the breast
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
NCT02993159 STU00204804
More Info

For more information on this study please contact us:

1-888-NU-STUDY
BTCRC GYN15-013: Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
The purpose of this study is to test the good and bad effects of the study drug, pembrolizumab, in combination with routine care using paclitaxel and ca…
The purpose of this study is to test the good and bad effects of the study drug, pembrolizumab, in combination with routine care using paclitaxel and carboplatin chemotherapy.
Participants will be adults with cancer in the lining of the uterus (endometrium) that has spread to other parts of the body or has returned after initial treatment.
Matei, DanielaMatei, Daniela
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02549209 STU00204968
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Purpose The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin. Overview The combination treatm…
Purpose The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin. Overview The combination treatment of ipilimumab and nivolumab could shrink a participant's cancer but it could also cause side effects. Researchers hope to learn if the study drugs will shrink the cancer by at least one-quarter compared to its present size. Both ipilimumab and nivolumab have already been FDA-approved to treat other cancers. However, ipilimumab and nivolumab are investigational and not FDA-approved for use in combination in treating rare cancers or cancers of unknown primary origin. Description of Treatment All study participants will get the same study drugs: ipilimumab and nivolumab. Participants will receive both study drugs through a vein on the first day of each cycle (or every 6 weeks), and they will receive nivolumab through a vein every 2 weeks. Participants will continue to receive study drugs until their disease gets worse or they experience bad side effects from the study drugs or their study doctor decides that they are not benefiting from the study drugs.
Some of the eligibility criteria include:

- Participants must be at least 18 years of age or older.

No other prior malignancy is allowed except for the following:

1. Adequately managed Stage I or II cancer from which the participant is currently in complete remission

2. Any other cancer from which the participant has been disease free for one year.

3. Adequately managed Stage I or II follicular thyroid or prostate cancer is also eligible, in which the participant is not required to be in complete remission

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02834013 STU00205572
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
NU 16H08: Phase II study of PET-directed frontline therapy with pembrolizumab and AVD for patients with classical Hodgkin lymphoma
The purpose of this research study is to evaluate a new drug, pembrolizumab, followed by chemotherapy, for the treatment of newly diagnosed classical Hodgkin lymphoma. Th…
The purpose of this research study is to evaluate a new drug, pembrolizumab, followed by chemotherapy, for the treatment of newly diagnosed classical Hodgkin lymphoma. The chemotherapy regimen is called “AVD” and includes three drugs: doxorubicin, vinblastine, dacarbazine. Pembrolizumab is currently FDA approved for the treatment of relapsed Hodgkin lymphoma, but is not approved for use in newly diagnosed patients. The ‘ABVD’ regimen of chemotherapy is the standard of care for the treatment of newly diagnosed classical Hodgkin lymphoma. Not all patients achieve a complete remission with ABVD, and older patients tolerate the regimen poorly. Patients who do not have a complete response to standard ABVD chemotherapy (meaning there is still evidence of disease on PET scans performed at the end of treatment), may be treated with radiation or a more intensive chemotherapy regimen. Patients who don’t achieve a complete remission with frontline treatment (refractory disease) or those who relapse require treatment with high dose chemotherapy and a stem cell transplant. Older patients, however, are not candidates for intensive chemotherapy or stem cell transplant. This is a phase II study of pembrolizumab followed by AVD (ABVD without bleomycin) for patients with newly diagnosed classical Hodgkin lymphoma. Some older patients may receive an additional one to two years of pembrolizumab maintenance.
Some of the eligibility criteria include:
• Patients must have a confirmed diagnosis of classical Hodgkin lymphoma.
• Patients must have previously untreated disease
• Patients must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Winter, Jane NormaWinter, Jane Norma
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03226249 STU00203707
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
DRUG CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
The main purpose of this study is to look at the safety, tolerability, and overall effectiveness (how well the …
The main purpose of this study is to look at the safety, tolerability, and overall effectiveness (how well the drug works) of nivolumab in combination with ipilimumab and nivolumab in combination with plantinum doublet chemotherapy in subjects with non-small cell lung cancer.
Mohindra, NishaMohindra, Nisha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02998528 STU00205030
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
NU UW16B13: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
Certain types of breast cancer test positive for overexpression HER2 (a protein involved in normal cell growth) and some test negative. Some patients may …
Certain types of breast cancer test positive for overexpression HER2 (a protein involved in normal cell growth) and some test negative. Some patients may have HER2-negative breast cancer with mutations in HER2. Neratinib is an investigational drug - meaning that it has not been approved by the U.S. Food and Drug Administration [FDA] - shown to be effective for treating HER2-positive breast cancer in clinical trials. An additional routine treatment involves a drug called Fulvestrant, which blocks the effects of estrogen in breast tissue. In this study, the uses of neratinib alone or in combination with Fulvestrant, will be studied, to see how the cancer responds to these treatments in each population.
Diagnosis with metastatic breast cancer at the time of screening
Diagnosis of metastatic breast cancer that is HER2-negative, but found to have a mutation in HER2 at the time of enrollment
Age of at least 18 years
Completion of radiation therapy and be at least 1 week from the last administration before starting study treatment
Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01670877 STU00205349
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of two …
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of two investigational drugs called nivolumab and ipilimumab in subjects with late stage skin cancer that have had their tumors completely removed, but are likely to have their cancer return.
All participants must be aged 18 years or older. Participants must have histologically confirmed melanoma that has been surgically removed.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03068455 STU00205248
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
(xIRB NCI-CIRB) SWOG 1512: A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)
The purpose of this study is to test any good and bad effects of the study drug MK-3475 (also called pembrolizumab). MK-3475 (pembr…
The purpose of this study is to test any good and bad effects of the study drug MK-3475 (also called pembrolizumab). MK-3475 (pembrolizumab) could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will cause the cancer to at least temporarily disappear in more than twenty percent of patients with melanoma that is not surgically removable. In patients with melanoma that is surgically removable, researchers also hope to learn if the study drug will cause the surgery to be more effective and avoid repeated surgery.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02775851 STU00205551
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent"
The purpose of this study is to compare any good and bad effects of using ipilimumab in combination with nivolumab to th…
The purpose of this study is to compare any good and bad effects of using ipilimumab in combination with nivolumab to the usual approach of using ipilimumab alone when treating melanoma that cannot be removed by surgery. The combination treatment of ipilimumab and nivolumab could stop a participant's melanoma from getting worse, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. Both ipilimumab and nivolumab have already been FDA-approved to treat other cancers. However, ipilimumab and nivolumab are investigational and not FDA-approved for use in combination in treating melanoma. This study has two treatment groups, Group 1 and Group 2. Participants in Group 1 will receive ipilimumab once every three weeks for up to four times. Participants in Group 2 will receive nivolumab and ipilimumab once every three weeks for up to four times.
Participants must be at least 18 years of age. Participants must have melanoma that cannot be removed by surgery. Participants have received an immunotherapy drug (a drug that helps the body’s immune system destroy cancer cells), and their cancer got worse while receiving that.
Sosman, JeffreySosman, Jeffrey
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03033576 STU00205856
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck
The purpose of this study is to find the best dose and the safety of an experimental (investigational) anti-cancer …
The purpose of this study is to find the best dose and the safety of an experimental (investigational) anti-cancer medicine called Nanoparticle Cisplatin (NC-6004) combined with Cetuximab and 5-Fluorouracil (5-FU) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. NC-6004 is made from the active part of cisplatin, which has been used to treat cancer and is not yet approved by the U.S. FDA. NC-6004 has not been approved yet by the U.S. Food and Drug Administration (FDA) or by any other Health Authority. The study will be open-label and will be conducted in 2 parts. An open-label trial is a type of clinical trial in which both researchers and participants know which treatment is being given.
Participants must be 18 years of age or older. Participants must have recurrent or metastatic squamous cell carcinoma of the head and neck.
Matsangou, MariaMatsangou, Maria
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03109158 STU00205385
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
DRUG CO39722: A PHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA.
The purpose of this study is to compare the efficacy a…
The purpose of this study is to compare the efficacy and safety of cobimetinib plus atezolizumab with the efficacy and safety of pembrolizumab in patients with a type of skin cancer called melanoma that has spread to other parts of the body (metastatic), cannot be removed by surgery (unresectable), and have not received any prior treatment.
Clinically confirmed Stage melanoma or unresectable Stage 3 melanoma, age 18 years or older
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00000419 STU00205830
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
This study is broken down into two phases. The purpose of Phase I is to determine the maximum safe dose of a d…
This study is broken down into two phases. The purpose of Phase I is to determine the maximum safe dose of a drug called MLN0128 for treatment of advanced liver cancer. The purpose of Phase II is to compare any good and bad effects of MLN0128 to the effects of sorafenib, the standard drug used to treat advanced liver cancer. This will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach to treat advanced liver cancer. The U.S. Food and Drug Administration (FDA) has approved the standard drug, sorafenib, for use in liver cancer. The study drug, MLN0128 should be considered “investigational” which means that this drug has not been approved by the FDA to treat any disease.
Must be 18 years or older. Participants must have a diagnosis of measurable advanced or metastatic liver cancer. Participants will receive either the study treatment until their cancer gets worse or they have severe side effects.
Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02575339 STU00206030
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Back to top